

POST GRADUATE TRAINING

- 2005-2007 University of Florida College of Medicine, Gainesville, FL, Fellow in the Advanced Postgraduate Program in Clinical Investigation (APPCI), funded by the NIH Clinical Research Curriculum Award (K30)

- 2006 American Heart Association, Fellowship
32nd Ten-day Seminar on the Epidemiology and Prevention of Cardiovascular Disease

- 1986-1987 University of California, San Francisco, Residency in Clinical Pharmacy

BOARD CERTIFICATION

- Licentiate in Pharmacy, California (inactive)
- Licentiate in Pharmacy, Florida (current)

PROFESSIONAL POSITIONS

- July 2012-Present Associate Professor with Tenure
University of Florida, College of Pharmacy
Department of Pharmacotherapy and Translational Research

- Mar 2009-Present Associate Professor
University of Florida, College of Pharmacy
Department of Pharmacotherapy and Translational Research

- July 2008-Feb 2009 Research Associate Professor
University of Florida, College of Medicine
Division of Cardiovascular Medicine

- Sept. 1999-Jun 2008 Research Assistant Professor
University of Florida, College of Medicine
Division of Cardiovascular Medicine

- Sept. 1999-Feb 2009 Associate Director, Clinical Trials Program
University of Florida, College of Medicine
Division of Cardiovascular Medicine
Gainesville, FL

Activities include the management of day to day operations of the cardiovascular clinical trials program, and the supervision of the research coordinators. Other responsibilities include the organization and management of the regulatory department for the clinical trials program.

- 1997-2004 Director, INVEST Pharmacy Coordinating Center
University of Florida, College of Medicine
Division of Cardiology
Gainesville, FL

Activities include the oversight of medication dispensing for 22,000 national and international patients enrolled in the INVEST trial.

- 1987-1999 Coordinator, Investigational Drug Service
Shands Hospital at the University of Florida

Gainesville, Florida
 Supervisor: Alan Knudsen, MS

Activities include developing and implementing an investigational drug service (IDS) in a large teaching institution. The IDS now controls medications for 390 different studies in both the inpatient and outpatient area. The IDS provides necessary drug and study information to all health care professionals and patients involved with the studies. Additionally, clinical research protocols are designed and written for the hospital by the IDS. A software program designed to control investigational drug data and inventory was developed here and is now marketed.

1994-1997 Director, Pharmacy Practice Residency
 Shands Hospital at the University of Florida
 Gainesville, Florida

Coordinate and facilitate the pharmacy practice residency at Shands Hospital, including recruiting, precepting, and overseeing the program.

1992-1998 Clinical Trials Program Liaison
 University Hospital Consortium's Clinical Practice Advancement Center (formerly Technology Advancement Center)
 Receive information about new clinical trials, and contact investigators who might be interested in conducting the trials.

1982-1987 Laboratory Assistant II
 UCSF Drug Studies Unit
 School of Pharmacy
 Director: Roger L. Williams, M.D.
 Activities include performing EKG's, blood drawing, sample processing, controlling and dispensing investigational drugs.

AWARDS AND HONORS

- 2016 Russell R. Miller Award, for substantial contributions to the literature, from the American College of Clinical Pharmacy
- 2016 Faculty of the American College of Clinical Pharmacy Research Institute Mentored Research Investigator Training Program (MeRIT)
- 2016 NHLBI Scientific Review Panel (Loan Repayment Program)
- 2015 Distinguished Investigator Award, American College of Clinical Pharmacy, Cardiology PRN
- 2015 Designated as a Master Mentor – 2014-2015 UF Mentor Academy
- 2015 Faculty of the ACCP Research Institute Mentored Research Investigator Training Program (MeRIT)
- 2015 NHLBI Scientific Review Panel (Loan Repayment Program)
- 2015 Distinguished Associate Award, American College of Cardiology
- 2014 Fellow, American College of Clinical Pharmacists
- 2013 Member, Academy of Research Excellence, University of Florida
- 2011 Drug Therapy Research Award – American Society of Health System Pharmacists
- 2011 Best Paper Award – American College of Clinical Pharmacy, Cardiology Practice and Research Network
- 2011 Top Population Science Paper

| | |
|------|--|
| 2010 | Hypertension, Journal of the American Heart Association |
| 2009 | Fellow, American College of Cardiology |
| 2009 | Featured Poster Award |
| 2009 | American Society of Hypertension, 24th Annual Scientific Meeting and Exposition, San Francisco, California |
| 2008 | ASHP Foundation Pharmacy Resident Practice-Based Research Grant Program Peer Review |
| 2008 | Clinical Science Award |
| 2008 | The Consortium for Southeastern Hypertension Control (COSEHC), 15 th Annual National Scientific Sessions, Baltimore, Maryland |
| 2007 | Vascular Biology / Blood Pressure Regulation |
| 2007 | American Heart Association Peer Review, Committee R2 |
| 2007 | Fellow, American Heart Association (FAHA.) and Council for High Blood Pressure Research. |
| 2001 | New Investigator Award |
| 1988 | American Heart Association, Council on Basic Cardiovascular Sciences, Seattle, Washington |
| 1987 | Roche Award for Outstanding Research Affecting Patient Care |
| 1987 | Outstanding Young Women of America |
| 1986 | Outstanding Student Service Award |
| | University of California, San Francisco |
| | School of Pharmacy |

COMMITTEE MEMBERSHIPS

| | |
|--------------|---|
| 2015-Present | Cardiovascular Team Section Leadership Council, American College of Cardiology |
| 2015-Present | Best Practices and Quality Improvement Committee, American College of Cardiology |
| 2014-Present | Faculty Development Committee, Chairperson |
| 2013-Present | College of Pharmacy, University of Florida |
| 2012-2014 | KL2 CTSI Committee |
| 2011-2014 | University of Florida |
| 2009-Present | Team Based Care Committee, American College of Cardiology |
| 2007-2012 | Mentoring Committee, American College of Clinical Pharmacy, |
| 2007-2013 | Cardiology Practice Research Network |
| 1987-2004 | Institutional Review Board, University of Florida |
| 1989-1999 | General Clinical Research Center Scientific Advisory Committee , |
| 1991-1995 | University of Florida |
| | Shands Hospital Biotechnology Committee (Subcommittee of Pharmacy and Therapeutics Committee) |

TEACHING EXPERIENCE

| | |
|---------------------|---|
| Sum 2015-present | PHAXXXX, Clinical Applications of Personalized Medicine |
| | Bioethics and informed consent; Statin Pharmacogenomics |
| Spring 2010-present | GMS6413, Hypertension Research |
| | Clinical Trials in Hypertension, Diabetes and Metabolic Syndrome and Hypertension |
| Fall 2009 –present | PHA 5782, Pharmacotherapy II |

Dyslipidemia, Stable Ischemic Heart Disease, Hypertension

| | |
|------------------|--|
| Spring 2010-2014 | PHA 6935, Practice and Procedures of the IRB |
| Fall 2008-2012 | GMS 7039, Intro to Clinical Translational Research Panel participant: "How I Got Funded" |
| Fall 2006, 2007 | GMS 6181, Intro to Clinical Translational Research "Out into the Community and Back to the Bench" |
| 2006-Present | PHA 56**, Clinical Pharmacogenomics "Ethical Conduct of Human Subjects Research" |
| 2000-2003 | Department of Medicine Resident Rotation Preceptor Cardiovascular Research |
| 1995-1999 | Basic and Clinical Research Course for Physicians and Fellows |
| 1987-1999 | Contemporary Pharmacy Systems for Pharm.D. Students University of Florida, College of Pharmacy |
| 1986-1987 | Clinical Pharmacy Preceptor University of California School of Pharmacy San Francisco, California |

Supervised Clinical Pharmacy students who were completing their clerkship rotations in the hospitals and clinics at UCSF and SFGH. Assisted with organizing the course for the Clinical Pharmacy students, completed student evaluations, and held conferences for the students.

RESEARCH SUPPORT AND PROJECTS

Extramural Funding –

U01 GM074492 (Cooper-DeHoff and Johnson) 8/1/2010 – 7/31/2015 NIH/NIGMS
Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)

HHSN268201100004C (Limacher) 10/1/10 – 9/30/15 NIH, NHLBI
Women's Health Initiative Extension 2010-2015

U01 HG007269 (Johnson) 5/1/2013 - 4/30/2017
NIH, National Human Genome Research Institute
Genomic Medicine Implementation: The Personalized Medicine Program

Intramural Funding –

UF CTSI 1/2014
Clinical Research Pilot Award: PI Cooper-DeHoff RM, The Effect of Low Furanocoumarin
Grapefruit Hybrid Juice Consumption on Midazolam Pharmacokinetics

South East Center for Integrative Metabolomics 6/2014
Pilot and Feasibility Project Award: PI Cooper-DeHoff, RM, A targeted pharmacometabolomic
investigation of the acylcarnitine pathway and incident impaired fasting glucose.

Completed Research

National Institutes of Health, K23 HL086558-01, January 2007-January 2012. Metabolic Effects of Antihypertensive Responses (MEAD). **Rhonda Cooper-DeHoff, Pharm D.** – Principal Investigator

ACCP Research Institute PPD bioanalytical fluid and Tissue Grant, Metabolic Effects of Antihypertensive Drugs. January 2010. **Rhonda Cooper-DeHoff, Pharm D.** – Principal Investigator.

National Institutes of Health, NHLBI Resequencing and Genotyping Service Award via the J. Craig Venter Institute. Awarded May 2008. Understanding the Relationship of Transcription Factor 7-like Gene (*TCF7L2*) Polymorphisms and Incidence of Diabetes in an Ethnically Diverse Hypertensive Heart Disease Population. **Rhonda Cooper-DeHoff, Pharm D.** – Principal Investigator

University of Florida, Clinical and Translational Science Institute. 10/2008-10/2009. PPAR γ Expression in Key Metabolic Organ Systems is Modulated by Treatment with Thiazide Diuretics and ACE Inhibition. **Rhonda Cooper-DeHoff, Pharm D.** – Principal Investigator

University of Florida, 2/2004 to 2/2007 WISE / Women Take Heart Collaboration. **Rhonda Cooper-DeHoff, Pharm.D.** – Principal Investigator

Cleveland Clinic and Pfizer, 02/06/07-12/29/07, *Prospective Randomized Evaluation of Celecoxib Integrated Safety, vs. Ibuprofen Or Naproxen-PRECISION*, Carl Pepine, M.D. and **Rhonda Cooper DeHoff, Pharm D.** - Co-Investigator

National Institutes of Health, U01 GM074492 (PI: J.A. Johnson), August 2005 – July 2010, Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR). **Rhonda Cooper-DeHoff, Pharm D.** – Co-Investigator

National Institutes of Health. 9/2003 – 8/2007, Hypertension Pharmacogenetics. Julie Johnson, PharmD, Carl Pepine, M.D., **Rhonda Cooper-DeHoff, Pharm.D.** – Co-Investigator

Pfizer Pharmaceuticals. 8/2001–2/2008, Effect of Sildenafil on Coronary and Systemic Vascular Function in women with chest pain. Carl J. Pepine, M.D.- PI, **Rhonda Cooper DeHoff, Pharm.D.** – Co-Investigator

Abbott Laboratories. 3/1997 to 12/2006, International Verapamil-trandolapril Study (INVEST) is a randomized, Controlled Clinical Trial Comparing a Calcium Antagonist Treatment Strategy with a Non-calcium Antagonist Treatment Strategy for the Control of Hypertension and Angina in a Primary Care Ambulatory Patient Population. Carl J. Pepine, M.D. - PI, **Rhonda Cooper-DeHoff, Pharm.D.** - Co-Investigator

University of Florida, 1/1996 to 1/2007. Evaluation of Lewis Phenotype as a Risk Factor for Coronary Artery Disease. **Rhonda Cooper-DeHoff, Pharm.D.**

Pfizer Pharmaceuticals. 4/2002 to 10/2006, A pilot study to determine the effect of Celecoxib 400mg and 800mg on markers of inflammation in patients with hypertension & coronary artery disease. **Rhonda Cooper-DeHoff, Pharm.D.** – Principal Investigator

Perry E. Foote Outcomes Research Small Grant Program, 7/2001 to 5/2004, A pilot study to determine the effect of Celecoxib 400mg and 800mg on markers of inflammation in patients with hypertension and coronary artery disease. **Rhonda Cooper-DeHoff, Pharm.D.** – Principal Investigator

Drug Use Evaluation of DNase 1994 During the First 6 Months of Use. **Rhonda Cooper, Pharm.D.**, and Sherry Ingram, Pharm.D.

Cost of Hospital Admissions as a Result of Phenytoin Adverse Drug Reactions. 1993 Lisa Daley, Pharm.D., **Rhonda Cooper, Pharm.D.**, and Randy Hatton, Pharm.D.

Prospective, Controlled, Third Party Blind, Randomized, Multi-center Comparison of the Safety and Efficacy of Ciprofloxacin plus Metronidazole (IV only and IV/PO) with that of Imipenem-Cilastatin for the Treatment of Patients with Intra-abdominal Infections. 1991 Stephen Vogel, M.D., Larry Aull, Pharm.D., and **Rhonda Cooper, Pharm.D.**

The Efficacy of Indomethacin Compared to Ibuprofen and Acetaminophen-diphenhydramine-hydrocortisone in the Treatment of Shaking Chills Associated with Amphotericin B. 1990 Stan Reents, Pharm.D., **Rhonda Cooper, Pharm.D.** and Vipul Singh, M.D.

An Assessment of the Readability and Comprehension of IRB Approved Informed Consent Forms. 1989 Rebecca Murgatroyd, Pharm.D. and **Rhonda Cooper, Pharm.D.**

A Multi-center, Open Label, Variable Dose Evaluation of Morphine Sustained Release Suspension Administered for 3 Days in the Treatment of Cancer Pain. 1988 **Rhonda M. Cooper, Pharm.D.** and David Oblon, M.D.

A Retrospective Analysis of the Effect of Investigational Studies on Current Ceftazidime Usage at Shands Hospital. 1988 **Rhonda M. Cooper, Pharm.D.**

Utilization of and Satisfaction with a New Investigational Drug Service. 1987 **Rhonda M. Cooper, Pharm.D.** and Becky Coleman, Pharm.D.

The Pharmacokinetics of Ketoprofen in the Elderly. 1987 **Rhonda M. Cooper, Pharm.D.**, Nancy Sambol, Pharm.D., and Roger L. Williams, M.D.

PROFESSIONAL OFFICES AND APPOINTMENTS

1987-1989 Secretary, North Central Florida Society of Hospital Pharmacists

1986-1987 Western Regional Alumni Director
Phi Delta Chi Pharmaceutical Fraternity

MEMBERSHIPS IN PROFESSIONAL ORGANIZATIONS

American College of Clinical Pharmacy
American Society of Hypertension
American Heart Association
American College of Cardiology
American Diabetes Association
Florida Society of Hospital Pharmacists
North Central Florida Society of Hospital Pharmacists

PUBLICATIONS

Articles in Refereed Journals:

1. **Cooper RM.** Potassium Iodide for Radiation Exposure. *Drug Intelligence and Clinical Pharmacy.* 1988; 22: 33-34.

2. Huang D, Harman E, Friedman B, Tanaka W, **Cooper RM**, Hendeles L. Effect of a leukotriene synthesis inhibitor (MK-886) on the early and late asthmatic response. *Chest* 1990;98:50S.
3. Hendeles L, Davison D, Blake K, Harman E, **Cooper RM**, Margolskee D. Leukotriene D₄ is an important mediator of antigen-induced bronchoconstriction: Attenuation of dual response with MK-571, a specific LTD₄ receptor antagonist. *J Allergy Clin Immunol* 1990;85:197.
4. Murgatroyd RJ, **Cooper RM**. Readability of informed consent forms. *Am J of Hosp Pharm* 1991;48:2651-2652.
5. Pepine CJ, Handberg E, Marks RG, Conlon M, **Cooper-DeHoff, RM**, Volkens P, Zelles P. Rationale and design of the INternational VErampil SR/Trandolapril STudy (INVEST): An internet-based randomized trial in coronary artery disease patients with hypertension. *J Am Coll Cardiol* 1998;32(5):1228-37.
6. Grant MB, Mames RN, Fitzgerald C, Hazariwala KG, **Cooper-DeHoff R**, Caballero S, Estes KS. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. *Diabetes Care* 2000;23(4):504-509.
7. **Cooper-DeHoff RM**, Handberg E, Heissenberg, C, Johnson, K. Electronic prescribing via the internet for a coronary artery disease and hypertension megatrial. *Clin Cardiol* 2001;24(11):V14-V16.
8. Conti CR, **Cooper-DeHoff RM**. How will INVEST and other hypertension trials change clinical practice? *Clin Cardiol* 2001;24(11):V24-V29.
9. Pepine CJ, **Cooper-DeHoff RM**, Weiss RJ, Koren M, Bittar N, Thadani U, Minkwitz MC, Michelson EL, and Hutchinson HG. Comparative Efficacy and safety of nisoldipine and amlodipine (CESNA-II) study investigators. Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. *Am J Cardiol* 2003;91(3):274-279.
10. Pepine CJ, Handberg EM, **Cooper-DeHoff RM**, Marks RG, Kowey P, Messerli FH, Mancina G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The INternational VErampil-Trandolapril STudy (INVEST). *JAMA* 2003;290(21):2805-2816.
11. Pepine CJ, **Cooper-DeHoff RM**. Cardiovascular therapies and risk for development of diabetes. *J Am Coll Cardiol* 2004;44(3):509-512.
12. **Cooper-DeHoff RM**, Handberg EM, Cohen J, Kowey P, Messerli F. Characteristics of contemporary patients with hypertension and coronary artery disease. *Clin Cardiol*. 2004;27(10):571-576.
13. Bakris GL, Gaxiola E, Messerli FH, Mancina G, Erdine S, **Cooper-DeHoff RM**, Pepine CJ; INVEST Investigators. Clinical outcomes in the diabetes cohort of the INternational VErampil SR-trandolapril STudy. *Hypertension* 2004;44(5):637-42.
14. Zineh I, **Cooper-DeHoff RM**, Wessel TR, Arant CB, Sleight P, Geiser EA, Pepine CJ. Global differences in blood pressure control and clinical outcomes in the INternational VErampil SR-trandolapril STudy (INVEST). *Clin Cardiol* 2005;28(7):321-328.
15. Elliott WJ, Hewkin AC, Kupfer S, **Cooper-DeHoff RM**, Pepine CJ. A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients. *J Clin Hypertension* 2005;7(11):654-663.
16. **Cooper-DeHoff RM**, Pepine CJ. Editorial: Ranolazine is associated with cardiovascular and metabolic improvement: A win-win for patients with diabetes. *Eur Heart J* 2006;27(1):5-6.
17. Pepine CJ, Kowey PR, Kupfer S, Kolloch RE, Benetos A, Mancina G, Coca A, **Cooper-DeHoff RM**, Handberg EM, Gaxiola E, Sleight P, Conti CR, Hewkin AC, Tavazzi L. Predictors of adverse outcomes among patients with hypertension and coronary artery disease. *J Am Coll Cardiol* 2006;47(3):547-551.

18. **Cooper-DeHoff RM**, Aranda JM, Gaxiola E, Cangiano JL, Garcia-Barreto D, Conti CR, Hewkin A, Pepine CJ. Blood pressure control and cardiovascular outcomes in high risk Hispanic patients – Findings from the International Verapamil SR – Trandolapril Study. *Am Heart J* 2006;151(5):1072-79.
19. **Cooper-DeHoff RM**, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC, Kupfer S, Pepine CJ. Predictors of Development of Diabetes Mellitus in Patients with Coronary Artery Disease Taking Antihypertensive Medications (Findings from the INternational VERapamil SR-Trandolapril STudy [INVEST]). *Am J Cardiol* 2006, 98:890-894.
20. Epstein, BJ and **Cooper-DeHoff, RM**. Effect of Ramipril on the Incidence of Diabetes – Letter to the Editor. *N Engl J Med*. 2007;356:523.
21. Bakris GL, **Cooper-DeHoff RM**, Zhou Q, Kupfer S, Champion A, Pepine CJ, for the INVEST Investigators. Dual Therapy in Hypertensive Patients with Coronary Artery Disease: The Role of Calcium Channel Blockers and B-Blockers. *Am. J. Cardiovasc. Drugs*. 2007; 7 Suppl. 1: 25-29.
22. Langaee TY, Gong Y, Yarandi HN, Katz DA, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. Association of CYP3A5 Polymorphisms with Hypertension and Antihypertensive Response to Verapamil. *Clinical Pharmacology & Therapeutics*. 2007. Vol. 81, No. 3, 386-391.
23. **Cooper-DeHoff RM**, Zhou Q, Gaxiola E, Cangiano JL, Garcia-Barreto D, Handberg E, Pepine CJ. Influence of Hispanic Ethnicity on Blood Pressure Control and Cardiovascular Outcomes in Women with CAD and Hypertension: Findings from INVEST. *Journal of Women's Health*, 2007;16:632-640.
24. Brunner M, **Cooper-DeHoff RM**, Gong Y, Karnes JH, Langaee TY, Pepine CJ, Johnson JA. Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/ Trandolapril [INVEST] Study). *Am J Cardiol* 2007;99:1549-1554.
25. Beitelshes AL, Gong Y, **Cooper-DeHoff RM**, Burt L, Stauffer LA, Pepine CJ, Johnson JA.. KCNM1B1 genotype influences response to verapamil. SR and adverse outcomes in the INternational VERapamil SR/Trandolapril STudy (INVEST). *Pharmacogenetics and Genomics* 2007;17:719-729.
26. Uretsky S, Messerli FH, Bangalore S, Champion A, **Cooper-DeHoff RM**, Zhou Q, Pepine, CJ. Obesity Paradox in Patients with Hypertension and Coronary Artery Disease. *The American Journal of Medicine*. 2007. 120;10: 863-870.
27. **Cooper-DeHoff RM**, Pepine CJ. Metabolic Syndrome and Cardiovascular Disease: Challenges and Opportunities. *Clinical Cardiol* 2007; 30, 593-597.
28. Coca A, Messerli FH, Benetos A, Zhou Q, Champion A, **Cooper-DeHoff RM**, Pepine CJ. Predicting Stroke Risk in Hypertensive Patients with Coronary Artery Disease: A Report from the INVEST. *Stroke*, 2008;39:343-348.
29. Kolloch R, Legler UF, Champion A, **Cooper-DeHoff RM**, Handberg E, Zhou Q, and Pepine CJ. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VERapamil-SR/trandolapril STudy (INVEST) *Eur Heart J*. 2008;29:1327-34.
30. Pacanowski MA, Zineh I, Li H, Johnson BD, **Cooper-DeHoff RM**, Bittner V, McNamara DM, Sharaf BL, Bairey Merz CN, Pepine CJ, Johnson JA. Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. *J Transl Med*. 2008. 6:1-11.
31. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, **Cooper-DeHoff RM**, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ. Postmenopausal Women with a History of Irregular Menses and Elevated Androgen Measurements at High Risk for Worsening Cardiovascular Event-Free Survival: Results from the National Institutes of Health--National Heart, Lung, and Blood Institute Sponsored Women's Ischemia Syndrome Evaluation. *J Clin Endocrinol Metab*. 2008 Apr;93(4):1276-84.

32. Gerhard T, Gong Y, Beitelshes AL, Mao X, Lobmeyer MT, **Cooper-DeHoff RM**, Langaee TY, Schork NJ, Shriver MD, Pepine CJ, Johnson JA; INVEST Investigators. Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENetic Substudy of the INternational VERapamil SR-trandolapril Study (INVEST-GENES). *Am Heart J*. 2008 Aug;156(2):397-404.
33. Pacanowski MA, Gong Y, **Cooper-DeHoff RM**, Schork N, Shriver M, Langaee T, Pepine CJ, Johnson J. beta-Adrenergic Receptor Gene Polymorphisms and beta-Blocker Treatment Outcomes in Hypertension. *Clin Pharmacol Ther*. 2008;84:715-21.
34. **Cooper-DeHoff RM**. Thiazide Induced Dysglycemia – It's Time To Take Notice. *Exp Rev of Card Ther* 2008;6:1291-1294.
35. Johnson AD, Gong Y, Wang D, Langaee TY, Shin J, **Cooper-DeHoff RM**, Schork NJ, Bindley P, Pepine CJ, Johnson JA, Sadee W. Promoter polymorphisms in ACE (angiotensin-I converting enzyme) associated with clinical outcomes in hypertension. *Clin Pharmacol Ther* 2009;85:36-44
36. **Cooper-DeHoff RM**, Pacanowski MA, Pepine, CJ. Cardiovascular Therapies and Associated Glucose Homeostasis: Implications across the Dysglycemia Continuum. *J Am Coll Cardiol* 2009;53:S28-34.
37. Denardo SJ, Messerlli FH, Gaxiola E, Aranda JM, **Cooper-DeHoff RM**, Handberg EM, Gong Y, Champion A, Zhou Q, Pepine, CJ. Characteristics and Outcomes of Revascularized Patients with Hypertension – An International Verapamil SR-Trandolapril Substudy. *Hypertension*.2009; 53(4):624-30.
38. Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, **Cooper-DeHoff RM**, Gums J, Curry RW, Gong Y, Beitelshes AL, Schwartz G, Turner ST. Pharmacogenomics of Antihypertensive Drugs: Rationale and Design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *Am Heart J* 2009;157:442-449.
39. Pacanowski MA, Zineh I, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. Genetic and Pharmacogenetic Associations Between NOS3 Polymorphisms, Blood Pressure, and Cardiovascular Events in Hypertension. *Am J Hypertens*, 2009;22:748-753.
40. Gulati M, **Cooper-DeHoff RM**, McClure C, Johnson BD, Shaw LJ, Handberg EM, Zineh I, Kelsey SF; Arnsdorf MF, Black HR, Pepine CJ, Bairey Merz CN. Adverse Cardiovascular Outcomes In Women with Nonobstructive Coronary Artery Disease: A Report From The National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study and The St James Women Take Heart (WTH) Project. *Arch Int Med* 2009;169: 843-850.
41. Gong Y, Handberg EM, Gerhard T, **Cooper-DeHoff RM**, Ried D, Johnson JA, Pepine CJ. Systolic Blood Pressure and Subjective Well-Being in Patients with Coronary Artery Disease. *Clinical Cardiology* 2009;32:627-632.
42. Karnes JH, **Cooper-DeHoff RM**. Antihypertensive Medications: Benefits of BP Lowering and Hazards of Metabolic Effects. *Exp Rev of Card Ther* 2009;7:689-702.
43. Beitelshes AL, Navara H, Wang D, Gong Y, Wessel J, Moss J, Langaee TY, **Cooper-DeHoff RM**, Sadee W, Pepine CJ, Schork NJ, Johnson JA. CACNA1C gene Polymorphisms, Cardiovascular Disease Outcomes and Treatment Response. *Circ Genetics* 2009;2:362-370.
44. Johnson JA, Gong Y, Bailey KR, **Cooper-DeHoff RM**, Chapman AB, Turner ST, Schwartz GL, Campbell K, Schmidt S, Beitelshes AL, Boerwinkle E, Gums JG. Hydrochlorothiazide and Atenolol Combination Antihypertensive Therapy: Effects of Drug Initiation Order. *Clin Pharmacol Ther* 2009;86:533-539.
45. Smith SM, Anderson SD, Wen S, Gong Y, Turner ST, **Cooper-DeHoff RM**, Schwartz GL, Bailey K, Chapman A, Hall KL, Feng H, Boerwinkle E, Johnson JA, Gums JG. Lack of Correlation Between Thiazide-Induced Hyperglycemia and Hypokalemia: Subgroup Analysis of Results from the Pharamcogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *Pharmacotherapy*, 2009;29:1157-1165.

46. **Cooper-DeHoff RM**, Handberg EM, Mancia G, Zhou Q, Champion A, Legler UF, Pepine CJ. INVEST revisited: Review of Findings from the International Verapamil SR Trandolapril Study. *Expert Rev Cardiovasc Ther.* 2009;7:1329-40.
47. **Cooper-DeHoff RM**, Wen S, Beitelshes AL, Zineh I, Gums JG, Turner ST, Gong Y, Hall K, Parekh V, Chapman AB, Boerwinkle E, Johnson JA. Impact of Abdominal Obesity on Incidence of Adverse Metabolic Effects Associated with Antihypertensive Medications. *Hypertension.* 2010;55:61-68.
48. Bavry AA, Anderson RD, Gong Y, Denardo SJ, **Cooper-DeHoff RM**, Handberg EM, Pepine CJ. Outcomes Among Hypertensive Patients with Concomitant Peripheral and Coronary Artery Disease: Findings from the International Verapamil-SR/Trandolapril Study. *Hypertension.* 2010;55:48-53.
49. **Cooper-DeHoff RM**. Drug Induced Diabetes – Understanding Which CV Drugs are Involved and Who Is At Highest Risk [transcript]. Cardiosource Web Site, American College of Cardiology Foundation. Available at <http://www.cardiosource.com/expertopinions/hottopics/article.asp?paperID=380>. Accessed February 9, 2010.
50. **Cooper-DeHoff RM**, Pepine CJ. The Use of Diuretics Plus Calcium Channel Blockers for Hypertension May Be Associated with a Higher risk of Myocardial Infarction but not Stroke Compared with the Combination of Diuretics plus Beta Blockers. *Evid Based Med* 2010;15:92-93.
51. Bairey Merz CN, Olson BM, McClure C, Yang Y, Symons J, Sopko G, Kelsey SF, Handberg EM, Johnson BD, **Cooper-DeHoff RM**, Sharaf B, Rogers WJ, Pepine CJ. A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: Results from the national Institutes of Health/National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE). *Am Heart J.* 2010;159:987-983.
52. Duarte JD, **Cooper-DeHoff RM**. Mechanisms for Blood Pressure-Lowering and metabolic Effects of Thiazide and Thiazide-Like Diuretics. *Expert Rev Cardiovasc Ther.* 2010;8:793-802.
53. **Cooper-DeHoff RM**, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients with Diabetes and Coronary Artery Disease. *JAMA.* 2010;304:61-68.
54. Denardo SJ, Gong Y, Nichols WW, Messerli FH, **Cooper-DeHoff RM**, Handberg EM, Champion A, Pepine CJ. Blood Pressure and Outcomes in Very Old Hypertensive Coronary Artery Disease Patients: An International Verapamil SR-Trandolapril Study (INVEST) Substudy. *Am J Med.* 2010;123:719-726.
55. Denardo SJ, Messerli FH, Gaxiola E, Aranda JM, **Cooper-DeHoff RM**, Handberg EM, Gong Y, Champion A, Zhou Q and Pepine CJ. Coronary Revascularization Strategy and Outcomes According to Blood Pressure (from the International Verapamil SR-Trandolapril Study (INVEST)). *Am J Cardiol* 2010;106:498-503.
56. Turner ST, Schwartz GL, Chapman AB, Beitelshes AL, Gums JG, **Cooper-DeHoff RM**, Boerwinkle E, Johnson JA, Bailey KR. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. *Am J Hypertens.* 2010;23:1014-1022.
57. Navare HH, Frye RF, **Cooper-DeHoff RM**, Shuster JJ, Hall K, Schmidt SOF, Turner ST, Johnson JA. A Pilot Study to Evaluate Atenolol Exposure and Risk for Development of Adverse Metabolic Effects. *Pharmacotherapy.* 2010, 30:872-878.
58. Niu Y, Gong Y, Langaee TY, Davis HM, Elewa H, Beitelshes AI, Moss JI, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. Genetic variation in the beta 2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the International Verapamil SR-Trandolapril Study GENETic Substudy (INVEST-GENES). *Circ Cardiovasc Genet* 2010;3:548-555.
59. Beitelshes AL, Johnson JA, Hames ML, Gong Y, **Cooper-DeHoff RM**, Wu J, Cresci S, Ma CX, Pepine CJ, Province MA, Spertus JA, McLeod HL. Aromatase gene

- polymorphisms are associated with survival among patients with cardiovascular disease in a sex-specific manner. *PLoS One* 2010;5:1-6
60. Lobbmeyer MT, Wang L, Zineh I, Turner ST, Gums JG, Chapman AB, **Cooper-DeHoff RM**, Beitelshes AL, Bailey KR, Boerwinkle EA, Pepine CJ, Johnson JA; Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive treated patients, *Pharmacogenet Genomics*; 2011;21(1):42-9.
 61. **Cooper-DeHoff RM**, Egelund EF, Pepine CJ. Blood Pressure Lowering in Patients with Diabetes – One Level may Not Fit All. *Nature Review Cardiol* 2011;8:42-9.
 62. Gong Y, Beitelshes AL, **Cooper-DeHoff RM**, Lobbmeyer MT, Langae TY, Wu J, Cresci S, Province MA, Spertus JA, Pepine CJ, Johnson JA. Chromosome 9p21 Haplotypes and Prognosis in White and Black Patients with Coronary Artery Disease. *Circ Cardiovasc Genet*. 2011; 4:169-178.
 63. Price ET, Pacanowski MA, Martin MA, **Cooper-DeHoff RM**, Pepine CJ, Zineh I, Johnson JA. Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study. *Pharmacogenetics and Genomics* 2011;21:333-340.
 64. Bavry AA, Khaliq A, Gong Y, Handberg EM, **Cooper-DeHoff RM**, Pepine CJ. Harmful effects of nonsteroidal anti-inflammatory drugs among patients with hypertension and coronary artery disease. *Am J Med* 2011;124(7):614-20.
 65. Denardo SJ, Wen X, Handberg EM, Bairey Merz CN, Sopko GS, **Cooper-DeHoff RM**, Pepine CJ. Effect of phosphodiesterase type 5 inhibition on microvascular coronary dysfunction in women: a Women's Ischemia Syndrome Evaluation (WISE) ancillary study. *Clin Cardiol*. 2011;34(8):483-7.
 66. Pauly DF, Johnson BD, Anderson RD, Handberg EM, Smith KM, **Cooper-DeHoff RM**, Sopko G, Sharaf BM, Kelsey SF, Merz CN, Pepine CJ. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). *Am Heart J*. 2011 Oct;162(4):678-84
 67. Davoodi-Semiromi A, **Cooper-DeHoff RM**. Correspondence regarding "Longterm treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats. *Biochem Pharmacol*. 2012;83:821.
 68. Smith SM, Gong Y, Turner ST, **Cooper-DeHoff RM**, Beitelshes AL, Chapman AB, Boerwinkle E, Bailey K, Johnson JA, Gums JG. Blood Pressure Responses and Metabolic Effects of Hydrochlorothiazide and Atenolol. *Am J Hypertens*. 2012;25:359-365.
 69. Saxena R, Elbers CC, Guo Y, Peter I, et al. Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. *Am J Hum Genet*, 2012; Feb 8. [Epub ahead of print] PMID: 22325160
 70. Duarte JD, Turner ST, Tran B, Chapman AB, Bailey KR, Gong Y, Gums JG, Langae TY, Beitelshes AL, **Cooper-DeHoff RM**, Boerwinkle E, Johnson JA. Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression. *Pharmacogenomics J*. 2012; epub ahead of print.
 71. Turner ST, Schwartz GL, Chapman AB, Beitelshes AL, gums JG, **Cooper-DeHoff, RM**, Boerwinkle E, Johnson JA, Bailey KR. Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. *J Transl Med* 2012;13;10:47.
 72. Duarte JD, Zineh I, Burkley B, Gong Y, Langae TY, Turner St, Chapman AB, Boerwinkle E, Gums JG, **Cooper-DeHoff RM**, Beitelshes AL, Bailey KR, Fillingim RB, Kone BC, Johnson JA. Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide. *J Transl Med* 2012; 22;10:56.

73. Davoodi-Semiromi A, Wasserfall CH, Xia CQ, **Cooper-DeHoff RM**, Wabitsch M, Claresalzl M, Atkinson M. The Tyroprostin agent AG-490 Prevents and Reverses Type 1 Diabetes in NOD Mice. *PLoS One*. 2012;7(5):e36079.
74. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, **Cooper-Dehoff RM**, Gong L, Klein TE, Wadelius M, Niemi M. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. *Clin Pharmacol Ther*. 2012;92(1):112-7.
75. Gerhard T, Delaney JA, **Cooper-Dehoff RM**, Shuster J, Brumback BA, Johnson JA, Pepine CJ, Winterstein AG. Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy. *BMC Med Res Methodol*. 2012 Aug 6;12(1):119.
76. Vandell AG, Lobbmeyer MT, Gawronski BE, Langaee TY, Gong Y, Gums JG, Beitelshes AL, Turner ST, Chapman AB, **Cooper-DeHoff RM**, Bailey KR, Boerwinkle E, Pepine CJ, Liggett SB, Johnson JA. G protein receptor kinase 4 (GRK4) polymorphisms: Beta-blocker pharmacogenetics and treatment related outcomes in hypertension. *Hypertension* 2012 Oct;60(4):957-64.
77. Gong Y, McDonough CW, Wang Z, Hou W, **Cooper-Dehoff RM**, Langaee TY, Beitelshes AL, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Turner ST, Johnson JA. Hypertension Susceptibility Loci and Blood Pressure Response to Antihypertensives - Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *Circ Cardiovasc Genet*. 2012;5:686-691.
78. Asselbergs FW, Guo Y, van Iperen EPA, Sivapalaratnam S, Tragante V, Lanktree MB, Lange LA, Almqvister Castillo B, Appelman YE, Barnard J, Baumert J, Beitelshes AL, Bhangale TR, Ida Chen YD, Gaunt TR, Gong Y, Hopewell JC, Johnson T, Kleber ME, Langaee TY, Li M, Li YR, Liu K, McDonough CW, Meijis MFL, Middelberg RPS, Musunuru K, Nelson CP, O'Connell JR, Padmanabhan S, Pankow JS, Pankratz N, Rafelt S, Rajagopalan R, Romaine SPR, Schork NJ, Shaffer J, Shen H, Smith EN, Tischfield SE, van der Most PJ, van Vliet-Ostaptchouk JV, Verweij N, Volcik KA, Zhang L, Bailey KR, Bailey KM, Bauer F, Boer JMA, Braund PS, Burt A, Burton PR, Buxbaum SG, Chen W, **Cooper-DeHoff RM**, et al. Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. *Am J Hum Genet* 2012, 91(5):823-38.
79. Davoodi-Semiromi A, Wasserfall CH, Hassanzadeh A, **Cooper-Dehoff RM**, Wabitsch M, Atkinson M. Influence of Tyroprostin AG490 on the expression of diabetes-associated markers in human adipocytes. *Immunogenetics*. 2013 65(1):83-90.
80. Guo Y, Lanktree MB, Taylor KC, Hakonarson H, Lange LA, Keating BJ; **Cooper-DeHoff RM**, et al. The IBC 50K SNP array BMI Consortium. Gene-centric meta-analyses of 108 912 individuals confirm known body mass index loci and reveal three novel signals. *Hum Mol Genet*. 2012 Oct 24. [Epub ahead of print]
81. Karnes JH, Langaee TY, McDonough CW, Chang SW, Ramos M, Catlin JR Jr, Casanova OE, Gong Y, Pepine CJ, Johnson JA, **Cooper-Dehoff RM**. Lack of association of the HMGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort. *J Transl Med*. 2013 Jan 9;11(1):12. [Epub ahead of print].
82. Ganesh SK, Tragante V, Guo W, Guo Y, Lanktree MB, Smith EN, Johnson T, Castillo BA, Barnard J, Baumert J, Chang YP, Elbers CC, Farrall M, Fischer ME, Franceschini N, Gaunt TR, Gho JM, Gieger C, Gong Y, Isaacs A, Kleber ME, Leach IM, McDonough CW, Meijis MF, Mellander O, Molony CM, Nolte IM, Padmanabhan S, Price TS, Rajagopalan R, Shaffer J, Shah S, Shen H, Soranzo N, van der Most PJ, Van Iperen EP, van Setten J, Vonk JM, Zhang L, Beitelshes AL, Berenson GS, Bhatt DL, Boer JM, Boerwinkle E, Burkley B, Burt A, Chakravarti A, Chen W, **Cooper-Dehoff RM**, et al. Loci influencing blood pressure identified using a cardiovascular gene-centric array. *Hum Mol Genet*. 2013 Jan 8. [Epub ahead of print]
83. McDonough CW, Burbage SE, Duarte JD, Gong Y, Langaee TY, Turner ST, Gums JG, Chapman AB, Bailey KR, Beitelshes AL, Boerwinkle E, Pepine CJ, **Cooper-DeHoff**

- RM**, Johnson JA. Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. *J Hypertens*. 2013;31(4):698-704.
84. Del-Aguila JL, Beitelshes AL, **Cooper-Dehoff RM**, Chapman AB, Gums JG, Bailey K, Gong Y, Turner ST, Johnson JA, Boerwinkle E. Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans. *Pharmacogenomics J*. 2014;14(1):35-40
 85. **Cooper-Dehoff RM**, Chang SW, Pepine CJ. Calcium antagonists in the treatment of coronary artery disease. *Curr Opin Pharmacol*. 2013 Feb 9. doi:pii: S1471-4892(13)00012-X. 10.1016/j.coph.2013.01.008. [Epub ahead of print]
 86. Calhoun M, Cross LB, **Cooper-DeHoff RM**. Clinical utility of β -blockers for primary and secondary prevention of coronary artery disease. *Expert Rev Cardiovasc Ther*. 2013 Mar;11(3):289-91.
 87. Wikoff WR, Frye RF, Zhu H, Gong Y, Boyle S, Churchill E, **Cooper-Dehoff RM**, Beitelshes AL, Chapman AB, Fiehn O, Johnson JA, Kaddurah-Daouk R. Pharmacometabolomics reveals racial differences in response to atenolol treatment. *PLoS One*. 2013;8(3):e57639. doi: 10.1371/journal.pone.0057639. Epub 2013 Mar 11.
 88. McDonough CW, Gong Y, Padmanabhan S, Burkley B, Langae TY, Melander O, Pepine CJ, Dominiczak AF, **Cooper-DeHoff RM**, Johnson JA. Pharmacogenomic association of non-synonymous SNPs in SIGLEC12, A1BG, and the Selectin Region and Cardiovascular Outcomes. *Hypertension*. 2013. [Epub ahead of print, May 20, 2013]
 89. **Cooper-DeHoff RM**, Bird ST, Nichols GA, Delaney JA, Winterstein AG. Antihypertensive Drug Class Interactions and risk for Incident Diabetes; a Nested Case Control Study. *Journal of the American Heart Association*, 2013, 2(3):e000125. doi: 10.1161/JAHA.113.000125.
 90. Turner ST, Boerwinkle E, O'Connell JR, Bailey KR, Gong Y, Chapman AB, McDonough CW, Beitelshes AL, Schwartz GL, Gums JG, Padmanabhan S, Hiltunen TP, Citterio L, Donner KM, Hedner T, Lanzani C, Melander O, Saarela J, Ripatti S, Wahlstrand B, Manunta P, Kontula K, Dominiczak AF, **Cooper-Dehoff RM**, Johnson JA. Genomic association analysis of common variants influencing antihypertensive responses to hydrochlorothiazide. *Hypertension* 2013;62:391-397.
 91. **Cooper-DeHoff RM**, Elliott WJ. Generic Drugs for Hypertension: Are They Really Equivalent? *Curr Hypertens Rep*. 2013;15:340-345.
 92. **Cooper-DeHoff RM**. The Next 10 years in antihypertensive treatment. *Expert Rev Cardiovasc Ther* 2013;11:669-671.
 93. Chapman AB, Cotsonis G, Parekh V, Schwartz GL, Gong Y, Bailey KR, Turner ST, Gums JG, Beitelshes AL, **Cooper-DeHoff RM**, Boerwinkle E, Johnson JA. Night Blood Pressure Responses to Atenolol and Hydrochlorothiazide in Black and White Patients with Essential Hypertension. *Am J Hypertens*. 2013. ePub ahead of press.
 94. Winchester DE, **Cooper-DeHoff RM**, Gong Y, Handberg EM, Pepine CJ. Mortality Implications of Angina and Blood Pressure in Hypertensive Patients with Coronary Artery Disease: New Data from Extended Follow-Up of the International Verapamil/Trandolapril Study (INVEST). *Clin Cardiol* 2013 36(8):442-7.
 95. Gong Y, McDonough CW, Beitelshes AL, O'Connell JR, Karnes JH, Turner ST, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Johnson JA, **Cooper-DeHoff RM**. PROX1 Gene Variant is Associated with Glucose Change after Antihypertensive Treatment. *Pharmacotherapy* 2014 Feb;34(2):123-30.
 96. McDonough CW, Gillis NK, Alsultan A, Chang SW, Kawaguchi-Suzuki M, Lang JE, Shahin MHA, Buford TW, El Roubi NM, Sá ACC, Langae TY, Gums JG, Chapman AB, **Cooper-DeHoff RM**, Turner ST, Gong Y, Johnson JA. Atenolol Induced HDL-C Change in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *PLoS One*. 2013 Oct 7;8(10):e76984. doi: 10.1371/journal.pone.0076984. eCollection 2013.

97. Karnes JH, Gong Y, Pacanowski MA, McDonough CW, Arwood MJ, Langae TY, Pepine CJ, Johnson JA, and **Cooper-DeHoff RM**. Impact of *TCF7L2* single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. *Pharmacogenet Genomics* 2013; 23(12):697-705.
98. Karnes JH, McDonough CW, Gong Y, Vo TT, Langae TY, Chapman AB, Gums JG, Beitelshes AL, Bailey KR, Del-Aguila J, Boerwinkle EA, Pepine CJ, Turner ST, Johnson JA, **Cooper-DeHoff RM**. Association of *KCNJ1* variation with change in fasting glucose and new onset diabetes during HCTZ treatment. *Pharmacogenomics J*. 2013; 13(5):430-436.
99. Bavry AA, Kumbhani DJ, Gong Y, Handberg EM, **Cooper-Dehoff RM**, Pepine CJ. Simple integer risk score to determine prognosis of patients with hypertension and chronic stable coronary artery disease. *J Am Heart Assoc*. 2013 Aug 15;2(4):e000205. doi: 10.1161/JAHA.113.000205.
100. Smith SM, Gong Y, Handberg E, Messerli FH, Bakris GL, Ahmed A, Bavry AA, Pepine CJ, **Cooper-Dehoff RM**. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. *J Hypertens*. 2014 Mar;32(3):635-43
101. Yoneyama S, Guo Y, Lanktree MB, Barnes MR, Elbers CC, Karczewski KJ, Padmanabhan S, Bauer F, Baumert J, Beitelshes A, Berenson GS, Boer JM, Burke G, Cade B, Chen W, **Cooper-Dehoff RM**, Gaunt TR, Gieger C, Gong Y, Gorski M, Heard-Costa N, Johnson T, Lamonte MJ, McDonough C, et al. Gene-centric meta-analyses for central adiposity traits in up to 57,412 individuals of European descent confirm known loci and reveal several novel associations. *Hum Mol Genet*. 2014 32(3):635-43 .
102. Hlatky MA, Ray RM, Burwen DR, Margolis KL, Johnson KC, Kucharska-Newton A, Manson JE, Robinson JG, Safford MM, Allison M, Assimes TL, Bavry AA, Berger J, **Cooper-Dehoff RM**, Heckbert SR, Li W, Liu S, Martin LW, Perez MV, Tindle HA, Winkelmayer WC, Stefanick ML. Use of medicare data to identify coronary heart disease outcomes in the Women's Health Initiative. *Circ Cardiovasc Qual Outcomes*. 2014. 7(1):157-62.
103. Bavry AA, Handberg EM, Huo T, Lerman A, Quyyumi AA, Shufelt C, Sharaf B, Bairey Merz CN, **Cooper-DeHoff RM**, Sopko G, Pepine CJ. Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: An ancillary study of the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). *Am Heart J*. 2014;167(6):826-32.
104. Tragante V, Barnes MR, Ganesh SK, Lanktree MB, Guo W, Franceschini N, Smith EN, Johnson T, Holmes MV, Padmanabhan S, Karczewski KJ, Almoguera B, Barnard J, Baumert J, Chang YP, Elbers CC, Farrall M, Fischer ME, Gaunt TR, Gho JM, Gieger C, Goel A, Gong Y, Isaacs A, Kleber ME, Leach IM, McDonough CW, Meijs MF, Melander O, Nelson CP, Nolte IM, Pankratz N, Price TS, Shaffer J, Shah S, Tomaszewski M, van der Most PJ, Van Iperen EP, Vonk JM, Witkowska K, Wong CO, Zhang L, Beitelshes AL, Berenson GS, Bhatt DL, Brown M, Burt A, **Cooper-Dehoff RM**, et al. Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood pressure related loci. *Am J Hum Genet*. 2014; 94(3):349-60.
105. Smith SM, Huo T, Delia Johnson B, Bittner V, Kelsey SF, Vido Thompson D, Noel Bairey Merz C, Pepine CJ, **Cooper-DeHoff RM**. Cardiovascular and Mortality Risk of Apparent Resistant Hypertension in Women With Suspected Myocardial Ischemia: A Report From the NHLBI-Sponsored WISE Study. *J Am Heart Assoc*. 2014 Feb 28;3(1):e000660. Epub ahead of print.
106. **Cooper-DeHoff RM**, Hou W, Weng L, Baillie RA, Beitelshes AL, Gong Y, Shahin MH, Turner ST, Chapman A, Gums JG, Boyle SH, Zhu H, Wikoff WR, Boerwinkle E, Fiehn O, Frye RF, Kaddurah-Daouk R, Johnson JA. Is a Diabetes-Linked Amino Acid Signature

- Associated with Beta Blocker-Induced Impaired Fasting Glucose? *Circ Cardiovasc Genetics*. 2014; 7(2):199-205.
107. Weitzel KW, Eelsey AR, Langaee TY, Burkley B, Nessler DR, Obeng AO, Staley BJ, Dong HJ, Allan RW, Liu JF, **Cooper-Dehoff RM**, Anderson RD, Conlon M, Clare-Salzler MJ, Nelson DR, Johnson JA. Clinical pharmacogenetics implementation: Approaches, successes, and challenges. *Am J Med Genetic C Semin Med Genet*. 2014;166:56-67.
 108. Vandell AG, McDonough CW, Gong Y, Langaee TY, Lucas AM, Chapman AB, Gums JG, Beitelshes AL, Bailey KR, Johnson RJ, Boerwinkle E, Turner ST, **Cooper-DeHoff RM**, Johnson JA. Hydrochlorothiazide-Induced Hyperuricemia in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. *J Intern Med*. 2014 Feb 12. [Epub ahead of print]. PMID: 24612202.
 109. Hamadeh IS, Langaee TY, Dwivedi R, Garcia S, Burkley BM, Chapman AB, Gums JG, Turner ST, Gong Y, **Cooper-DeHoff RM**, Johnson JA. Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. *Clin Pharmacol Ther*. 2014 Mar 17. doi: 10.1038/clpt.2014.62. [Epub ahead of print]
 110. Karnes JH, Gong Y, Arwood MJ, Gums JG, Hall K, Limacher MC, Johnson JA, and **Cooper-DeHoff RM**. Alteration in fasting glucose after prolonged treatment with a thiazide diuretic. *Diabetes Res Clin Pract*. 2014 Jun;104(3):363-9.
 111. Voils SA, **Cooper-DeHoff RM**. Association between high sensitivity C-reactive protein and metabolic syndrome in subjects completing the National Health and Nutrition Examination Survey (NHANES) 2009-10. *Diabetes & Metabolic Syndrome: Clinical Research and Reviews*. 2014 Apr-Jun;8(2):88-90.
 112. Moore MJ, Gong Y, Hou W, Hall K, Schmidt SO, Curry RW, Beitelshes AL, Chapman AB, Turner ST, Schwartz GL, Bailey K, Boerwinkle E, Gums JG, **Cooper-DeHoff RM**, Johnson JA. Predictors for Glucose Change in Hypertensive Participants Following Short-term Treatment with Atenolol or Hydrochlorothiazide. *Pharmacotherapy*. 2014, Nov;34(11):1132-40.
 113. Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, Maxwell WD, McLeod HL, Krauss RM, Roden DM, Feng Q, **Cooper-DeHoff RM**, Gong L, Klein TE, Wadelius M, Niemi M. The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLC01B1 and simvastatin-induced myopathy: 2014 update. *Clin Pharmacol Ther*. 2014 Oct;96(4):423-8.
 114. Winterstein AG, Kubilis P, Bird S, **Cooper-DeHoff RM**, Nichols GA, Delaney JA. Misclassification in assessment of diabetogenic risk using electronic health records. *Pharmacoepidemiol Drug Saf*. 2014 Aug;23(8):875-81.
 115. Bangalore S, Gong Y, **Cooper-DeHoff RM**, Pepine CJ, Messerli FH. 2014 Eighth Joint National Committee panel recommendation for blood pressure targets revisited: results from the INVEST study. *J Am Coll Cardiol* 2014;64:784-93.
 116. Owusu-Obeng A, Weitzel KW, Hatton RC, Staley BJ, Ashton J, **Cooper-DeHoff RM**, Johnson JA. Emerging Roles for Pharmacists in Clinical Implementation of Pharmacogenomics. *Pharmacotherapy* 2014 Oct;34(10):1102-12.
 117. Bavry AA, Gong Y, Handberg EM, **Cooper-DeHoff RM**, Pepine CJ. Impact of aspirin according to type of stable coronary artery disease: Insights from a large international cohort. *Am J Med* 2015 Feb;128(2):137-43.
 118. Del-Aguila JL, **Cooper-DeHoff RM**, Chapman AB, Gums JG, Beitelshes AL, Bailey K, Turner ST, Johnson JA, Boerwinkle E. Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide. *Pharmacogenomics J*. 2015 Apr;15(2):153-7.
 119. Fontana V*, McDonough CW*, Gong Y, El Roubi NM, Sá ACC, Taylor KD, Chen Y-D I, Gums JG, Chapman AB, Turner ST, Pepine CJ, Johnson JA, **Cooper-DeHoff RM**. Large-Scale Gene-centric Analysis Identifies Polymorphisms for Resistant Hypertension. *J Am Heart Assoc*. 2014 Nov 10;3(6):e001398 PMID: 25385345. *These authors contributed equally to this work.

120. Denardo SJ, Gong Y, **Cooper-DeHoff RM**, Farsang C, Keltai M, Szirmai L, Messerli FH, Bavry AA, Handberg EM, Mancina G, Pepine CJ. Effects of verapamil SR and atenolol on 24-Hour blood pressure and heart rate in hypertension patients with coronary artery disease: an International Verapamil SR-Trandolapril ambulatory monitoring substudy. *PLOS ONE*. 2015 Apr 2;10(4):e0122726.
121. Weng L, Quinlivan E, Gong Y, Beitelshes AL, Shahin MH, Turner ST, Chapman AB, Gums JG, Johnson JA, Frye RF, Garrett TJ, **Cooper-DeHoff RM**. Association of Branched and Aromatic Amino Acids Levels with Metabolic Syndrome and Impaired Fasting Glucose in Hypertensive Patients. *Metab Syndr Relat Disord*. 2015 Jun;13(5):195-202. PMID:25664967.
122. Chittani M, Zaninello R, Lanzani C, Frau F, Ortu MF, Salvi E, Fresu G, Citterio L, Braga D, Piras DA, Carpini SD, Velayutham D, Simonini M, Argiolas G, Pozzoli S, Troffa C, Glorioso V, Kontula KK, Hiltunen TP, Donner KM, Turner ST, Boerwinkle E, Chapman AB, Padmanabhan S, Dominiczak AF, Melander O, Johnson JA, **Cooper-DeHoff RM**, Gong Y, Rivera NV, Condorelli G, Trimarco B, Manunta P, Cusi D, Glorioso N, Barlassina C. TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. *J Hypertens*. 2015 Jun;33(6):1301-9.
123. Hiltunen TP, Donner KM, Sarin AP, Saarela J, Ripatti S, Chapman AB, Gums JG, Gong Y, **Cooper-DeHoff RM**, Frau F, Glorioso V, Zaninello R, Salvi E, Glorioso N, Boerwinkle E, Turner ST, Johnson JA, Kontula KK. Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. *J Am Heart Assoc*. 2015 Jan 26;4(1):e001521. doi: 10.1161/JAHA.115.001778.
124. Smith SM and **Cooper-DeHoff RM**. Home blood pressure monitoring with patient-initiated drug titration reduces blood pressure in high-risk patients with hypertension. *Evid Based Med*. 2015 Apr;20(2):58.
125. El Rouby N and **Cooper-DeHoff RM**. Genetics of Resistant Hypertension: a Novel Pharmacogenomics Phenotype. *Curr Hypertens Rep*. 2015;17:583-594.
126. Gong Y, McDonough CW, Beitelshes AL, El Rouby N, Hiltunen TP, O'Connell JR, Padmanabhan S, Langae TY, Schmidt SO, Curry RW, Gums JG, Donner KM, Kontula KK, Bailey KR, Boerwinkle E, Takahashi A, Tanaka T, Kubo M, Pepine CJ, Chapman AB, Turner ST, **Cooper-DeHoff RM**, Johnson JA. *PTPRD* Gene Associated with Blood Pressure Response to Atenolol and Resistant Hypertension in Hypertensive Individuals. *J Hypertens*. 2015 Nov;33(11):2278-85.
127. Biel NM, Santostefano KE, DiVita BB, El Rouby N, Carrasquilla SD, Simmons C, Nakanishi M, **Cooper-DeHoff RM**, Johnson JA, Terada N. Vascular Smooth Muscle Cells From Hypertensive Patient-Derived Induced Pluripotent Stem Cells to Advance Hypertension Pharmacogenomics. *Stem Cells Transl Med*. 2015 Dec;4(12):1380-90.
128. Weng L, Taylor KD, Chen YD, Sopko G, Kelsey SF, Bairey Merz CN, Pepine CJ, Miller VM, Rotter JI, Gulati M, Goodarzi MO, **Cooper-DeHoff RM**. Genetic Loci Associated with Nonobstructive Coronary Artery Disease in Caucasian Women. *Physiol Genomics*. 2016 Jan;48(1):12-20.
129. **Cooper-DeHoff RM** and Johnson JA. Hypertension Pharmacogenomics: In Search of Personalized Treatment Approaches. *Nat Rev Nephrol*. 2016 Feb;12(2):110-22.
130. Khaliq A, Johnson BD, Anderson RD, Bavry AA, **Cooper-DeHoff RM**, Handberg EM, Bairey Merz CN, Nicholls SJ, Nissen S, Pepine CJ. Relationships between components of metabolic syndrome and coronary intravascular ultrasound atherosclerosis measures in women without obstructive coronary artery disease: the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation Study. *Cardiovasc Endocrinol*. 2015 Jun;4(2):45-52.
131. Gong Y, Wang Z, Beitelshes AL, McDonough CW, Langae TY, Hall K, Schmidt SO, Curry RW, Gums JG, Bailey KR, Boerwinkle E, Chapman AB, Turner ST, **Cooper-DeHoff RM**, Johnson JA. Pharmacogenomic Genome-wide Meta-analysis of blood pressure response to beta-blockers in hypertensive African Americans. *Hypertension*. 2016 Mar;67(3):556-63.

132. Hamadeh IS, Shahin MH, Lima SM, Oliveira F, Wilson L, Khalifa SI, Langaee TY, **Cooper-DeHoff RM**, Cavallari LH, Johnson JA. Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians. *Clin Transl Sci*. 2016 Feb;9(1):36-42.
133. Rotroff, D., Shahin, M., Gurley, S., Zhu, H., Motsinger-Reif, A., Meisner, M., Beitelshees, A., Fiehn, O., Johnson, J., El-Badawi, M., Frye, R., Gong, Y., Weng, L., **Cooper-DeHoff, RM.**, Kaddurah-Daouk, R. Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes. *CPT Pharmacometrics Syst Pharmacol*. 2015 Nov;4(11):669-79.
134. Zhu HJ, Langaee TY, Gong Y, Wang X, Pepine CJ, **Cooper-DeHoff RM**, Johnson JA, Markowitz JS. CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril. *Eur J Clin Pharmacol*. 2016 Jun;72(6):681-7
135. Chang SW, Gong Y, McDonough CW, Langaee TY, Nasiri Kenari N, Beitelshees AL, Gums JG, Chapman AB, Turner ST, Johnson JA, **Cooper-DeHoff RM**. Melatonin Pathway and Atenolol-Related Glucose Dysregulation: Is there a Correlation? *Clin Transl Sci*. 2016 Apr 23;10:11. doi: 10.1186/s40246-016-0073-3.
136. Ben S, **Cooper-DeHoff RM**, Flaten HK, Evero O, Ferrara TM, Spritz RA, Monte AA. Multiplex SNaPshot – a new simple and efficient CYP2D6 and ADRB1 genotyping method. *Human Genomics* 2016;10:11 DOI 10.1186/s40246-016-0073-3.
137. Cardiovascular Disease and 10-Year Mortality in Postmenopausal Women with Clinical Features of Polycystic Ovary Syndrome. Merz CN, Shaw LJ, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip DE, **Cooper-DeHoff RM**, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ. *J Women's Health* 2016 June. Online ahead of print.

ABSTRACTS:

Peer Reviewed abstract presented at national and international meetings

1. Pepine CJ, Conlon M, Handberg-Thurmond E, Marks RG, **Cooper-DeHoff RM**, Kolb HR. A 'paper-less' study on optimal treatment strategies for hypertension and CAD: Pilot phase data from the INternational VErapamil-trandolapril STudy (INVEST). *J Am Coll Cardiol* 1998;31(2):211A.
2. **Cooper-DeHoff RM**, Handberg EM, Marks RG, Conlon M, Kolb HR, Bristol H, and Pepine CJ for the INVEST Investigators. Control of blood pressure in a population of women with hypertension and CAD using an Internet-based electronic prescribing system. *Am J Hypertension* 2000;13(4):117A.
3. **Cooper-DeHoff RM**, Handberg EM, Bristol HA, Kolb HR, Gaxiola E, Cangiano J, Pepine CJ. Characteristics and blood pressure responses of 6,057 Hispanic hypertensive patients with coronary artery disease enrolled in the INVEST. *J Am Coll Cardiol* 2001;37(2):216A.
4. **Cooper-DeHoff RM**, Handberg EM, Bristol H, Kolb M, Keltai R, Kolloch S, Erdine G, Mancina C, Pepine CJ. A comparison of European vs non-European hypertensive patients with co-existing coronary artery disease: An analysis from the total randomized sample of the INVEST. *J of Hypertension* 2001;19(S2):S189.
5. **Cooper-DeHoff RM**, Handberg EM, Bristol H, Kolb H, Pepine CJ. Blood pressure control in a cohort of patients with diabetes and ischemic heart disease. American Heart Association Scientific Conference on Molecular, Integrative, and Clinical Approaches to Myocardial Ischemia 2001;P125.
6. **Cooper-DeHoff RM**, Handberg EM, Bristol HA, Pepine CJ, for INVEST Investigators. Ethnicity and blood pressure control in patients with diabetes and coronary artery disease. *Am J Hypertension* 2002;15(4):194A.

7. **Cooper-DeHoff RM**, Handberg EM, Bristol HA, Kolb HR, Cangiano J, Cohen JD, Erdine S, Gaxiola E, Keltai M, Kolloch R, Kowey P, Mancía G, Messerli F, Pepine CJ for INVEST Investigators. Characteristics predicting blood pressure responses in 22,599 patients with hypertension and coronary artery disease. *Am J Hypertension* 2002;15(4):116A.
8. **Cooper-DeHoff RM**, Bristol HA, Pepine CJ. Systolic blood pressure control in diabetics and nondiabetics with hypertension and coronary artery disease. *J Am Coll Cardiol* 2003;41(6):320A.
9. **Cooper-DeHoff RM**, Bristol HA, Pepine CJ. Ethnic differences in systolic blood pressure control in hypertensive patients with coronary artery disease. *Am J Hypertension* 2003;16(5):27A.
10. **Cooper-DeHoff RM**, Gaxiola E, Cangiano JL, Barreto D, Conti, CR, Pepine CJ. Blood pressure reduction and CV outcomes in hypertensive Hispanics, Blacks and Caucasians with coronary artery disease: The International Verapamil Trandolapril Study. *Circulation*. 2003;108(17): IV-450.
11. **Cooper-DeHoff RM**, Bakris G, Cohen J, Messerli F, Erdine S, Bristol H, Pepine CJ. Reduced risk of new onset diabetes in hypertensive coronary artery disease patients treated with a calcium antagonist vs. a beta blocker regimen: the International Verapamil/Trandolapril Study. *Circulation* 2003;108(17):IV-750.
12. Messerli FH, **Cooper-DeHoff RM**, Kupfer SR, Pepine CJ. Lean Body Mass is Associated with the Highest Incidence of Mortality and Cardiovascular Morbidity in Hypertensive Patients with Coronary Artery Disease: Results from the International Verapamil SR/trandolapril Study (INVEST) Presented at 1st Congress, World Congress on the Insulin Resistance Syndrome, 2003.
13. Cohen JD, **Cooper-DeHoff RM**, Bakris GL, Conti R, Pepine CJ. Increased systolic blood pressure is associated with new diabetes in hypertensive patients with coronary artery disease. *Diabetes* 2004;53(2):A85.
14. **Cooper-DeHoff RM**, Kolloch R, Messerli FH, Handberg EM, Pepine CJ. Blood pressure control, angina episodes, and cardiovascular outcomes in patients with ischemia: the International Verapamil-Trandolapril Study. *J Am Coll Cardiol* 2004;43(5):483A.
15. Mancía G, **Cooper-DeHoff RM**, Hewkin AC, Kupfer SR, Pepine CJ. Association of BP control and frequency of mortality and CV morbidity in hypertensive patients with CAD: the International Verapamil SR-trandolapril Study. *Am J Hypertension* 2004;17:116A.
16. Mancía G, Hewkin A, **Cooper-DeHoff R**, Champion A, Pepine C. Uncontrolled blood pressure is risk equivalent to diabetes and prior myocardial infarction for cardiovascular outcomes: The International Verapamil SR-trandolapril Study. *Eur Heart J* 2004;25:662.
17. Zineh I, Ma CX, Wessel TR, Arant CB, **Cooper-DeHoff R**, Pauly DF, McGorray SP, Bairey Merz CN, Pepine CJ, Johnson JA. Influence of adrenergic system polymorphisms and nongenetic factors on obstructive coronary artery disease (CAD) in women: Results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). *Circulation* 2004;110(17):III-353.
18. Pepine CJ, Hewkins A, **Cooper-DeHoff RM**, Champion A, Mancía G. Outcome benefits of BP control in older CAD patients with hypertension: The International Verapamil SR-trandolapril Study (INVEST). *Circulation* 2004;110(17):III-731.
19. **Cooper-DeHoff RM**, Aranda JM Jr., Handberg EM, Zhou Q, Pepine CJ. Blood pressure control and cardiovascular outcomes in Hispanic women with coronary artery disease hypertension: Findings from the International Verapamil-Trandolapril Study. *Circulation* 2005;111(4):E76.
20. Gong Y, Beitelshes AL, Stauffer L, Gaston K, Sloan A, Yarandi HN, Langae TY, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. Beta 2-adrenergic receptors (B2AR) polymorphism and anti-hypertension response to beta-blocker therapy in the INVEST trial. *Clin Pharmacol Ther* 2005;77(2):P22. Presented as a poster presentation at the

- American Society for Clinical Pharmacology and Therapeutics 106th Annual Meeting, Orlando, FL, March 2005.
21. Beitelshes AL, Gong Y, **Cooper-DeHoff RM**, Moss JI, Pepine CJ, Johnson JA. Variable blood pressure response to verapamil by KCNMB1 genotype. *Clin Pharmacol Ther* 2005;77(2):P97. Presented as an oral presentation at the American Society for Clinical Pharmacology and Therapeutics 106th Annual Meeting, Orlando, FL, March 2005.
 22. Pepine C, Coca A, Messerli F, Benetos A, Zhou Q, Champion A, **Cooper-DeHoff RM**. Stroke risk in hypertensive patients with coronary artery disease: The International Verapamil SR-trandolapril Study (INVEST). *J Am Coll Cardiol* 2005;45(3):424A.
 23. Elliott W, Hewkin A, Champion A, **Cooper-DeHoff RM**, Pepine CJ. E-prescription database analysis supports use of combination therapy in hypertensive patients with CAD in INVEST. *Am J Hypertension* 2005;18:58A.
 24. **Cooper-DeHoff RM**, Qian Zhou, Pepine CJ. BP control and CV outcomes in Hispanic and Nonhispanic women with CAD and hypertension: Findings from INVEST. *Am J Hypertension* 2005;18:104A.
 25. Messerli F, **Cooper-DeHoff RM**, Champion A, Hewkin A, Pepine CJ. Lean body mass is associated with increased incidence of mortality and cardiovascular morbidity in hypertensive patients with coronary artery disease: The International Verapamil-SR-trandolapril Study (INVEST). *Am J Hypertension* 2005;18:148A.
 26. **Cooper-DeHoff RM**, Gaxiola E, Zhou Q, Handberg EM, Pepine CJ. Verapamil SR-based antihypertensive strategy reduces risk of new onset diabetes in Hispanic patients with coronary artery disease and hypertension: Findings from the International Verapamil SR-trandolapril Study (INVEST). *J Am Diabetes Assoc* 2005;54(1):1047P.
 27. Gerhard T, Gong Y, Beitelshes AL, Lobmeyer M, Schiefelbein L, Langae TY, **Cooper-DeHoff RM**, Johnson JA. Association between CV outcomes, diuretic use and the α -adducin gene: Results from the International Verapamil SR-trandolapril Study (INVEST). *Circulation* 2005;112(17):II-608.
 28. Shaw L, Johnson B, **Cooper-DeHoff RM**, Bittner V, Kelsey S, Reis S, Sopko G, Pepine C, Sharaf B, Bairey Merz N. Importance of socioeconomic status as a predictor of cardiovascular outcome in women. *Circulation* 2005;112(17):II-808.
 29. Langae TY, Yarandi HN, Katz DA, **Cooper-DeHoff RM**, Kehoe JM, Klocman AS, Pepine CJ, Johnson JA. Differences in verapamil response between CYP3A5 genotypes. *Clin Pharmacol Ther* 2006;79(2):P12.
 30. Brunner M, Karnes JH, Gong Y, Langae TY, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. Association of angiotensin II type I receptor (AGTR1) 1166A>C polymorphism with blood pressure response to ace inhibitor in a subgroup of patients of the International Verapamil CR/trandolapril Study (INVEST). *Clin Pharmacol Ther* 2006;79(2):P14.
 31. Gong Y, Beitelshes AL, Stauffer LA, Langae TY, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. Beta adrenergic receptors polymorphisms are associated with response to beta-blocker therapy in the Internal Verapamil SR-Trandolapril Study (INVEST). *Clin Pharmacol Ther* 2006;79(2):P30.
 32. Beitelshes AL, Gong Y, **Cooper-DeHoff RM**, Burt L, Stauffer LA, Pepine CJ, Johnson JA. KCNMB1 genotype associated with cardiovascular outcomes in the International Verapamil SR/trandolapril Study (INVEST). *Clin Pharmacol Ther* 2006;79(2):P41, 2006.
 33. Johnson JA, Karnes JH, Brunner M, Gong Y, Langae TY, **Cooper-DeHoff RM**, Pepine CJ. Lack of association of the angiotensin II type I receptor (AGTR1) 1166A>C polymorphism with cardiovascular and cerebrovascular outcomes in a subgroup of patients of the International Verapamil SR/trandolapril Study (INVEST). *Clin Pharmacol Ther* 2006;79(2):P43.
 34. Handberg E, Gong Y, **Cooper-DeHoff RM**, Ried LD, Pepine CJ. Can an assessment of subjective well being predict outcomes in patients with hypertension and coronary artery disease? A report from the International Verapamil-SR/Trandolapril Study. *J Am Coll Cardiol* 2006; 47(4):300A.

35. **Cooper Dehoff RM**, Handberg EM, Zhou Q, Champion A, Pepine CJ, and Cohen JD. Larger BMI and Higher Systolic Blood Pressure Are Associated with Increased Risk of Newly Diagnosed Diabetes in Hypertensive Patients With Coronary Artery Disease: Findings from the International Verapamil SR-Trandolapril Study (INVEST). *Circulation*, 2006; 113(8):E351.
36. Gong Y, Handberg EM, Gerhard T, **Cooper-DeHoff RM**, Johnson JA, Pepine CJ, Univ. FL, Gainesville, FL. Association of Systolic Blood Pressure (SBP) and Health Related Quality of Life in Patients with Coronary Artery Disease: An Analysis from the International Verapamil SR trandolapril Study (INVEST). *Circulation*, 2006;114 (18):II-2758.
37. **Cooper-DeHoff RM**, McClure CK, Johnson B, Gulati M, Shaw LJ, Handberg EM, Zineh I, Kelsey S, Arnsdorf MF, Black HR, Bairey Merz CN, Pepine CJ. Adverse Cardiovascular Outcomes in Women with No Obstructive Coronary Artery Disease: A Report From The NHLBI-sponsored WISE Study and the St James WTH Project. *Circulation* 2006;114:II339.
38. Shaw LJ, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, **Cooper-DeHoff RM**, Handberg EM, Berga S, Johnson BD, Bittner V, Rogers W, Pepine CJ, Bairey Merz CN. Cardiovascular Event-Free Survival in Post-Menopausal Women with Polycystic Ovary Syndrome: Results from the Women's Ischemia Syndrome Evaluation. Presented at AHA Scientific Sessions, Chicago, IL. Nov. 2006, *Circulation*, 2006; 114 (18).
39. **Cooper-Dehoff RM**, Gerhard T, Gong Y, Handberg EM, Messerli FH, Pepine CJ, Blood Pressure < 120/80 mmHg is Risky in Elderly CAD Patients: Findings from the International Verapamil SR Trandolapril Study (INVEST) Abstract. *Circulation*. Feb. 2007. Vol. 115, No.8, e258, P168.
40. McClure CK, Johnson BD, Gulati M, **Cooper-DeHoff RM**, Shaw LS, Handberg E, Zineh I, Kelsey SF, Arnsdorf M, Black H, Bairey CN, Pepine CJ. The Role of the Framingham Risk Score in Symptomatic Women: A Report from the NHLBI-Sponsored Women's Ischemia Study and the St. James Women Take Heart Project. *CVD Epidemiology and Prevention*. 2007, e253, P146.
41. Pacanowski MA, Gong Y, Langae Ty, **Cooper-DeHoff RM**, Schork NJ, Pepine CJ, Johnson JA. B2-adrenergic receptor polymorphisms and antihypertensive treatment outcomes in the International Verapamil SR/trandolapril Study – GENetic Substudy (INVEST-GENES). *Clin. Pharmacol. Ther.* 2007; 81 (S1):S34. Presented as a poster at the American Society for Clinical Pharmacology and Therapeutics 108th Annual Meeting, Anaheim, CA. March 2007.
42. Schentrup AM, Nino G, Gong Y, Lima JJ, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. LTA4H variant confers drug therapy –dependant reduced risk of cardiovascular events in INVEST (International Verapamil SR/Trandolapril study) *Clin. Pharmacol Ther.* 2007; 81 (SI): S35.
43. Merz CB, Olson M, McClure C, Symons J, Sopko G, Kelsey S, Handberg-Thurmond E, Johnson BD, **Cooper-DeHoff R**, Sharaf B, Rogers W, and Pepine C. Chronic CAD: New Insights For Medical Therapy and Revascularization: Abstract 2450: A Randomized Controlled Trial of Low Dose Hormone Therapy on Myocardial Ischemia in Postmenopausal Women with No Obstructive Coronary Artery Disease: Results from the NHLBI-sponsored WISE *Circulation*, Oct 2007; 116: II 539.
44. Midwall S, Anderson RD, Johnson D, Handberg E, **Cooper-Dehoff R**, Smith K, Pepine C, In Women without Obstructive Coronary Artery Disease, Endothelial-Dependent and Non-Endothelial Dependent Coronary Reactivity Dysfunction are Associated with Different Types of Adverse Outcomes. The NHLBI Women's Ischemia Syndrome Evaluation (WISE) [2870]. ABS Oral Session AOP.45.2: Chronic CAD: Pathophysiology and Prognosis 2:30-2:45p #2870 - Tuesday, Nov. 6, 2007, AHA *Circulation*, Oct 2007; 116: II 639.
45. Bairey-Merz C, Olson M, McClure C, Symons J, Sopko G, Kelsey S, Handberg-Thurmond E, Johnson BD, **Cooper-DeHoff R**, Sharaf B, Rogers W, Pepine C. A

- Randomized Controlled Trial of Low Dose Hormone Therapy on Myocardial Ischemia in Postmenopausal Women with No Obstructive Coronary Artery Disease: Results from the NHLBI-sponsored WISE. ABS Oral Session AOP.45.1: Chronic CAD: New Insights for Medical Therapy and Revascularization 9:45-10a #2450 – Tuesday, Nov. 6, 2007, AHA.
46. Denardo SJ, Messerli FH, Gaxiola E, **Cooper-DeHoff RM**, Handberg EM, Champion A, Zhou Q, Pepine CJ. Association of “J-shaped” curves and coronary revascularization status: A substudy of the INVEST. ABS Oral Session AOP.96.4: Coronary Atherosclerosis and Events. 10:45-11a #3704 - Wednesday, Nov. 7, 2007, AHA
 47. Pacanowski MA, Zineh I, Welder GJ, Adicks J, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. NOS3 polymorphisms do not associate with adverse clinical outcomes in elderly hypertensives with cardiovascular disease: Analysis of the INternational VERapamil SR-trandolapril STudy – GENetic Substudy (INVEST-GENES). Clin Pharmacol Ther 2008;83(S1):S83. Poster at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, April 2008.
 48. Pacanowski MA, **Cooper-DeHoff RM**, Gong Y, Schork NJ, Pepine CJ, Johnson JA. Diabetes risk associated with β_1 -adrenergic receptor polymorphisms differs by antihypertensive drug therapy: Results from the INternational VERapamil SR/ trandolapril STudy – GENetic Substudy (INVEST-GENES). Clin Pharmacol Ther 2008;83(S1):S83. Poster at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, April 2008.
 49. H.A. Navare, A.L. Beitelshes, Pharm D, MPH, Y. Gong, PhD, T.Y. Langae, PhD, **R.M.Cooper-Dehoff**, Pharm D, C.J.Pepine, MD, J.A.Johnson, Pharm D. CACNA1C Polymorphisms and Cardiovascular Outcomes in the International Verapamil SR/Trandolapril Study – Genetic Substudy (Invest-Genes). PT-10, Clinical Pharmacology and Therapeutics, 2008; 83 (S1):S4
 50. Price ET, Martin MA, Pacanowski M, **Cooper-DeHoff RM**, Pepine C, Johnson JA, Zineh I. Liver X receptor- α gene variability and cardiovascular risk in the INternational VERapamil SR/Trandolapril STudy – GENetic Substudy (INVEST-GENES). *Clinical Pharmacology & Therapeutics* (2008) 83, S66. doi:10.1038/sj.clpt.2008.44.
 51. Martin MA, Price ET, Pacanowski M, **Cooper-DeHoff RM**, Pepine C, Johnson JA, Zineh I. MADD variants and risk of cardiovascular events in the INternational VERapamil SR/Trandolapril STudy – GENetic Substudy (INVEST-GENES). *Clinical Pharmacology & Therapeutics* (2008) 83, S82–S83. doi:10.1038/sj.clpt.2008.46.
 52. **Cooper-DeHoff RM**, Pepine CJ. Investigation of the early effects of ACE-I on Glucose Intolerance During Treatment with HCTZ in Patients with Hypertension and Metabolic Syndrome. Oral presentation at the Consortium for Southeastern Hypertension Control 15th Annual Scientific Sessions, 2008.
 53. **Cooper-DeHoff RM**, Pepine CJ. Dysglycemia During Treatment with HCTZ in patients with Hypertension and Metabolic Syndrome. Poster at the American Heart Association, Scientific Session, *Circulation*, 2008, 118:S889.
 54. Niu Y, Langae TY, Gong Y, Moss JI, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. DNA Variations in Voltage-gated Calcium Channel Beta 2 Subunit (CACNB2) Gene, Functional Consequences, and Association with Adverse Cardiovascular Outcomes in the INternational VERapamil SR-trandolapril STudy-GENetic Substudy. Poster at the American Heart Association, Scientific Session, *Circulation*, 2008, 118:S885.
 55. **Cooper-DeHoff RM**, Gong Y, Marin J, Rosen A, Handberg EM, Johnson JA, Pepine CJ. Long-term Mortality Associated with New Onset Diabetes in Hypertensive CAD Patients Following Exposure to Antihypertensive medications: Findings from the INternational VERapamil SR/Trandolapril Study. *J Am Coll Cardiol* 2009, 0910-7:A224.
 56. Welder G, Price E, Duarte J, Handberg EM, Pepine CJ, **Cooper-DeHoff, RM**. PPAR γ Downregulation – A Novel Mechanism to Explain HCTZ Associated Dysglycemia in Patients with Hypertension and Metabolic Syndrome. Poster at the American Society of

- Hypertension, 24th Annual Scientific Meeting and Exposition, San Francisco, California, *J Clin Hypertension* 2009;11:A108.
57. Hames ML, Welder GJ, Wittmann J, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA, Beitelshes AL. Aromatase genotype in the INternational VERapamil SR/trandolapril Study (INVEST). *Pharmacotherapy* 2009;29:272e. Presented as a poster at the 2009 American College of Clinical Pharmacy Annual Meeting, October 18-21, 2009.
 58. Winchester DE, Gong Y, Handberg EM, **Cooper-DeHoff RM**, Pepine CJ. Incident or Continued Angina During Hypertension Treatment is Associated with Increased Risk of Death, MI or Stroke Among Patients with Known CAD: A Substudy of the International Verapamil SR / Trandolapril Study (INVEST). *Circulation*. 2009;120:S440-S441.
 59. Davis HM, Allen B, Gong Y, **Cooper-DeHoff RM**, Pepine CJ, Johnson JA. Clinical Association of Variation in the Beta 2 Regulatory Subunit of the Voltage-Gated Calcium Channel (CACNB2) With Outcomes in Hypertensive Coronary Artery Disease (CAD) Patients. *Clin Pharmacol Ther* (2010) 87, S2.
 60. Moore MJ, Chik VPW, Gong Y, Langaee T, Chapman AB, Schwartz GL, Turner ST, Gums JG, **Cooper-DeHoff RM**, Beitelshes AL, Johnson JA. Association between melatonin receptor 1B single nucleotide polymorphisms (SNPs) and response to antihypertensive drugs. *Clin Pharmacol Ther*. 2010;87(1):S45. American Society for Clinical Pharmacology and Therapeutics 111th Annual Meeting, Atlanta, GA, March 2010.
 61. Karnes JH, George AM, Gong Y, Langaee TY, Stauffer LA, Burkley BM, Pepine CJ, Johnson JA, **Cooper-DeHoff RM**. New onset diabetes risk associated with antihypertensive therapy in hypertensive coronary artery disease patients is modified by a single nucleotide polymorphism in the L-type calcium channel alpha 1c subunit (CACNA1C). *Clin Pharmacol Ther* 2010;87(S1):S45. Presented as a poster at the American Society for Clinical Pharmacology and Therapeutics 111th Annual Meeting, Atlanta, GA. March 2010.
 62. Bavry AA, Khaliq A, Gong Y, Handberg EM, **Cooper-DeHoff RM**, Pepine CJ. Effects of Chronic Nonsteroidal Anti-Inflammatory Drugs among Patients with Hypertension and Coronary Artery Disease - Post-hoc Analysis from the INVEST Trial. *Circulation* 2010;122:A12424. Oral Presentation at the American Heart Association Scientific Sessions, Chicago IL. November 2010.
 63. Park K, Egelund E, Wen X, **Cooper-DeHoff RM**, Bairey Merz CN, Handberg EM, Johnson BD, Sopko G, Johnson JA, Pepine CJ. Serotonin Transporter Gene Polymorphism in Women with Suspected Ischemia: A Report from the NHLBI-sponsored WISE. *Circulation* 2010;122:A20055. Poster Presentation at the American Heart Association Scientific Sessions, Chicago IL. November 2010.
 64. Gong Y, Beitelshes AL, Lobmeyer MT, Langaee TY, **Cooper-DeHoff RM**, Wu J, Spertus JA, Province MA, Pepine CJ, Johnson JA. Chromosome 9p21 SNPs Haplotypes are Associated with Cardiovascular Outcomes in Patients with Coronary Artery Disease. *Circulation* 2010;122:A16925. Oral Presentation at the American Heart Association Scientific Sessions, Chicago IL. November 2010.
 65. Vandell AG, Lobmeyer MT, Gawronski B, Langaee TY, Gong Y, Beitelshes AL, Gums JG, Turner ST, Chapman AB, **Cooper-DeHoff RM**, Liggett SB, Johnson JA. Influence of G Protein Kinase 4 (GRK4) Polymorphisms on Blood Pressure Response to the β Blocker Atenolol. *Clin Pharmacol Ther* 2011;89:S74. Presented at the American Society of Clinical Pharmacology and Therapeutics 2011 Annual Meeting, Dallas, Texas March 2011.
 66. Davis HM, Gong Y, Pepine CJ, **Cooper-DeHoff RM**, Johnson JA. Genetic Variation in the Calcium Signaling Pathway and Association with Outcomes in Hypertensive Coronary Artery Disease Patients. *Clinical Pharmacology & Therapeutics* (2011) 89 S1: S20. Presented at the American Society of Clinical Pharmacology and Therapeutics 2011 Annual Meeting, Dallas, Texas March 2011.

67. Moore MJ, Gong Y, Hou W, Chapman AB, Langaee TY, Schwartz GL, Turner ST, Gums JG, Bailey K, Boerwinkle E, Beitelshes AL, **Cooper-DeHoff RM**, Johnson JA. Clinical Predictors of Dysglycemic Effects Associated with Use of Beta Blockers and Thiazide Diuretics. *Clin Pharmacol Ther.* 2012;91(1):S24-25. Presented at the American Society of Clinical Pharmacology and Therapeutics 2012 Annual Meeting, National Harbor, MD March 2012
68. Karnes JH, McDonough CW, Gong Y, Langaee TY, Pepine CJ, Johnson JA, **Cooper-DeHoff RM**. Alpha adducin-1 (*ADD1*) single nucleotide polymorphism (SNP) associated with new onset diabetes risk with hydrochlorothiazide (HCTZ) therapy in the International Verapamil SR Trandolapril Genetic Substudy (INVEST-GENES). *Clin Pharmacol Ther* 2012; 91 (S1): S21, Presented at the American Society of Clinical Pharmacology and Therapeutics 2012 Annual Meeting, National Harbor, MD March 2012
69. Bavry AA, Gong Y, Kumbhani DJ, Kowey P, Haththotuwa EK, Handberg EM, **Cooper-DeHoff RM**, Pepine, CJ. Simple prediction of long-term mortality among hypertensive patients with coronary artery disease: New data from an extended follow up of the International Verapamil-SR/Trandolapril Study (INVEST). *J Am Coll Cardiol.* 59(13 Suppl):E1496, 2012. Presented at the American College of Cardiology Scientific Sessions 2012. Chicago, IL.
70. Winchester DE, Gong Y, **Cooper-DeHoff RM**, Handber E, Pepine C. Mortality associated with angina and blood pressure control among hypertensive patients with coronary artery disease: new data from extended follow-up of the International Verapamil/Tradolapril Study. *J Am Coll Cardiol.* 59(13 Suppl):E1458, 2012. Presented at the American College of Cardiology Scientific Sessions 2012. Chicago, IL.
71. **Cooper-DeHoff RM**, Gong Y, Handberg E, Messerli F, Bakris G, Ahmed A, Bavry A, Pepine C. Treatment-resistant blood pressure among patients with coronary artery disease—cause for concern: new data from the extended follow-up of the International Verapamil SR-Trandolapril Study (INVEST). *J Am Coll Cardiol.* 59(13 Suppl):E1498, 2012. Presented at the American College of Cardiology Scientific Sessions 2012. Chicago, IL.
72. Khaliq A, Johnson BD, Anderson R, Bavry A, **Cooper-DeHoff RM**, Handberg E, Bairey Merz CN, Pepine C. Relationships between components of metabolic syndrome and coronary intravascular ultrasound (IVUS) atherosclerosis measures in women without obstructive coronary artery disease: The NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. *J Am Coll Cardiol.* 59(13 Suppl):E1742, 2012 Presented at the American College of Cardiology Scientific Sessions 2012. Chicago, IL.
73. **Cooper-DeHoff RM**, Shuster J, Lo M, Handberg E, Davoodi-Semiromi A, Pepine CJ. Early effects of ace inhibition on glucose tolerance during thiazide treatment in patients with metabolic syndrome. *J Clin Hypertens* 2012;14 Suppl 1 :44. Presented at the American Society of Hypertension Annual Meeting 2012, New York, NY.
74. Bavry AA, Kumbhani DJ, Gong Y, Handberg EM, **Cooper-DeHoff RM**, Pepine CJ. Prediction tool for adverse events among patients with hypertension and chronic stable coronary artery disease. *Circulation.* 2012;126:A11945. Presented at the American Heart Association 2012 Scientific Sessions, Los Angeles, CA.
75. **Cooper-DeHoff RM**, Bird ST, Nichols GA, Delaney JC, Winterstein AG. Association of antihypertensive drug classes, alone or in combination with incident diabetes: a nested case-control study. *Circulation.* 2012;126:A11073. Presented at the American Heart Association 2012 Scientific Sessions, Los Angeles, CA.
76. **Cooper-DeHoff RM**, Garvan C, Delaney JA, Winterstein AG, Bavry A, Howard BV, Chen C, Manson J, Phillips LS, Liu S, Song Y, Shorr RI, Limacher M, and Women's Health Initiative Investigators. Chronic utilization of medications with metabolic effects and risk for incident diabetes in postmenopausal women. *Circulation.* 2012;126:A10050. Presented at the American Heart Association 2012 Scientific Sessions, Los Angeles, CA.

77. **Cooper-DeHoff RM**, Hou W, Baillie R, Beitelshes AL, Gong Y, Chapman AB, Gums JG, Turner ST, Boyle SH, Zhu H, Wikoff WR, Fiehn O, Frye RF, Kaddurah-Daouk R, Johnson JA. Pharmacometabolomics reveals a novel signature for predicting beta blocker associated impaired fasting glucose. *Circulation*. 2012;126:A11088. Presented at the American Heart Association 2012 Scientific Sessions, Los Angeles, CA.
78. Gong Y, Moore MJ, Karnes JH, McDonough CW, Wang Z, Langae TY, Beitelshes AL, Turner ST, Chapman AB, Gums JG, Bailey K, Boerwinkle E, Johnson JA, **Cooper-DeHoff RM**. Fasting Glucose Loci Associated with Glucose Response to Antihypertensives-Results from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR). *Clin Pharmacol Ther* 2013; 93 (S1): S28
79. Gong Y, McDonough CW, Wang Z, Langae TY, Beitelshes AL, Gums JG, Bailey KR, Boerwinkle E, Chapman AB, Turner ST, **Cooper-DeHoff RM**, Johnson JA. Genome-wide Association Analysis (GWAS) of Blood Pressure Response to Atenolol-Results from Pharmacogenomic Evaluation of Antihypertensive Responses Study. *Clin Pharmacol Ther* 2014; 95 (S1): S16. Oral presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting on March 20, 2014 Atlanta, GA.
80. Chang S, McDonough CW, Gong Y, Pepine CJ, Johnson JA, **Cooper-DeHoff RM**. A Pharmacogenomic Genome-wide Association Study (GWAS) for New onset diabetes in the International Verapamil SR-Trandolapril Study (INVEST). *Clin Pharmacol Ther* 2014; 95 (S1): S59. Oral presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting on March 20, 2014 Atlanta, GA.
81. Sa AC, Webb A, Gong Y, Langae T, Turner S, Chapman A, Gums J, Scherer S, **Cooper-DeHoff RM**, Sadee W, Johnson JA. Identifying Genes Differentially Expressed Associated with Extreme Blood Pressure Response to Hydrochlorothiazide monotherapy. Abstract/Program 732M. Poster presented at the 64th Annual Meeting of The American Society of Human Genetics, October 20, 2014 in San Diego, CA
82. El Rouby N., McDonough CW., Gong Y., Pepine CJ., Takahashi A., Tanaka T., Kubo M., **Cooper-DeHoff RM.**, Johnson JA., Genome-wide association study of resistant hypertension in INVEST. Poster 702M. Presented at the 64th Annual Meeting of The American Society of Human Genetics, October 20, 2014. San Diego, CA.
82. Winterstein AG, **Cooper-DeHoff RM**, Kubilis P, Nichols G, Delaney JAC. Diabetogenic effects of atypical antipsychotics – exploration of measurement bias. 30th Conference of Pharmacoepidemiology & Therapeutic Risk Management, October 24-27, 2014, Taipei, Taiwan. *Pharmacoepi Drug Saf* 2014;23(S1):142-143. Spotlight poster winner – Methods Special Interest Group.
83. Chang S, Gong Y, McDonough CW, Nasiri-Kenari N, Langae T, Beitelshes AL, Gums JG, Chapman AB, Turner ST, Johnson JA, **Cooper-DeHoff RM**. Correlating the Melatonin (MT) Pathway with Atenolol Associated Glucose Dysregulation in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study., Presidential Trainee Awards. *Clin. Pharmacol. Ther.* 2015, 97: S17. doi:10.1002/cpt.48
84. Shahin MH, Gong Y, Langae T, Beitelshes AL, Rotroff DM, Chapman AB, Gums JG, Turner ST, Motsinger-Reif A, Frye RF, Fiehn O, Johnson JA, **Cooper-DeHoff RM**, Han X, Kaddurah-Daouk R. Metabolomics, Genomics and Lipidomics Reveal Novel Signatures of Hydrochlorothiazide Response in Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study. 2015, Poster Session I. *Clinical Pharmacology & Therapeutics*, 97: S30.
85. Shahin MH, Rotroff DM, Gong Y, Langae T, McDonough CW, Beitelshes AL, Garrett TJ, Chapman AB, Gums JG, Turner ST, Motsinger-Reif A, Frye RF, Scherer SE, Sadee W, Fiehn O, **Cooper-DeHoff RM**, Kaddurah-Daouk R, Johnson JA. Integrating Metabolomics and Genomics Reveals Novel Biomarkers of Hydrochlorothiazide Response in Pharmacogenomic Evaluation Of Antihypertensive Responses (Pear) Study. (2015), Presidential Trainee Awards. Oral Session III. *Clinical Pharmacology & Therapeutics*, 97: S11.

86. **Cooper-DeHoff RM**, Weng L, Culver J, Gardell SJ, Petucci CJ, Morse AM, Frye RF, Gums J, Beitelshes AL, Borum PR, Johnson JA, Garrett, TJ, McIntyre LM. Pharmacometabolomics Identifies Acylcarnitines Associated with Beta blocker Induced Fasting Glucose Alterations. *Metabolomics 2015*, 11th International Conference of the Metabolomics Society, San Francisco, CA. Selected by NIH for travel award.
87. Solayman MH, Langae T, Gong Y, El-Hamamsy M, El-Wakeel L, Boerwinkle E, Chapman A, Turner S, Gums J, Beitelshes A, **Cooper-DeHoff RM**, Badary O, Johnson JA. Association of Plasma MicroRNA with Antihypertensive Response to Beta Blockers. *Clinical Pharmacology in Drug Development*. 2105; 4(S1) 58-5.,
88. Shahin MH, Sa AC, Webb A, Gong Y, Langae T, McDonough CW, Beitelshes AL, Chapman AB, Gums JG, Turner ST, Frye RF, Scherer SE, Sadee W, **Cooper-DeHoff RM**, Johnson JA. Identifying a Novel Hypertension Genetic Signature Influencing the Blood Pressure Response to Hydrochlorothiazide Treated Patients. Program/Abstract #674. Presented at the 65th Annual Meeting of The American Society of Human Genetics, October 7th, 2015 in Baltimore, MD.
89. Sa AC, Webb A, Gong Y, McDonough CW, Langae T, Turner ST, Beitelshes AL, Chapman AB, Boerwinkle E, Gums JG, Scherer S, **Cooper-DeHoff RM**, Sadee W, Johnson JA. Molecular Markers of Blood Pressure Response to Thiazide Diuretics Identified Through Whole Transcriptome RNA-Seq Analysis, Program/Abstract #656. Presented at the 65th Annual Meeting of The American Society of Human Genetics, October 7th, 2015 in Baltimore, MD.
90. El Rouby N, McDonough CW, Y. Gong , McClure LA, Mitchell BD, Horenstein RB, Talbert RL, Takahashi A, Tanaka T, Kubo M, Pepine CJ, **Cooper-DeHoff RM**, Benavente OR, Shuldiner AR, Johnson JA. Novel genetic loci for resistant hypertension discovered through a genome-wide association approach (GWAS) in the International Verapamil SR-Trandolapril Study (INVEST) and the Secondary Prevention of Subcortical Strokes (SPS3) Study. Program/Abstract # 665. Presented at the 65th Annual Meeting of The American Society of Human Genetics, October 8th, 2015 in Baltimore, MD.
91. A. C. Sa, A. Webb, Y. Gong, C.W. McDonough, M.H. Shahin, T. Y. Langae, S.T. Turner, A. L. Beitelshes, A. B. Chapman, E. Boerwinkle, J.G. Gums, S. Scherer, **R. M. Cooper-DeHoff**, W. Sadee, J. A. Johnson. Hypertension (HTN)/Blood Pressure (BP) Signature Genes and BP Response to Thiazide Diuretics (TD): Results From Pear and Pear-2 Studies. . *Clinical Pharmacology & Therapeutics* 2016, 99: S19 (PT23).
92. M. H. Shahin, A.C. Sa, A. Webb, Y. Gong, T. Langae, C. W. McDonough, A. Riva, A. L. Beitelshes, A. B. Chapman, J. G. Gums, S. T. Turner, R. F. Frye, S. E. Scherer, W. Sadee, **R. M. Cooper-DeHoff**, J. A. Johnson. Finding a Needle in the Haystack for Thiazide Diuretic Response Using Genomics/Transcriptomics in the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study. *Clinical Pharmacology & Therapeutics* 2016, 99: S19.
- 93.

PATENTS

US Patent No. 5,991,731

Title: Method and System for Interactive Prescription and Distribution of Prescriptions in Conducting Clinical Studies

UF Reference Number: 1682

INVITED JOURNAL REFEREE:

1. Psychosomatic Medicine
2. Pharmacotherapy

3. Journal of Human Hypertension
4. Clinical Cardiology
5. Circulation
6. Long Term Care Interface
7. British Journal of Clinical Pharmacology
8. Pharmacogenomics
9. Expert Review of Cardiovascular Therapy
10. Pharmacogenetics and Genomics
11. Lancet
12. Archives of Internal Medicine
13. JAMA
14. Journal of Women's Health
15. Nature Communications

EDITORIAL ACTIVITIES:

Editorial Board – Cardiology Today
Cardiovascular Pharmacology Section

Invited Quarterly Column – Cardiology Today, Pharmacology Consult

| | |
|---------------|--|
| November 2006 | FDA: Separate Ibuprofen and Aspirin |
| February 2007 | Grapefruit – Drug Interaction: Important Considerations for Heart Disease Patients |
| May 2007 | With OTC Simvastatin, U.K.'s Statin Prescriptions Down |
| August 2007 | Taking Steps to Reduce NSAID Risks |
| November 2007 | Patients Beware: Ways to minimize medication errors |
| February 2008 | Genotype-guided warfarin dosing now a reality. An NIH study planned for this year will assess multiple outcomes related to warfarin safety and efficacy. |
| May 2008 | Despite efforts, limited efficacy exists for dietary supplements, p.16 |
| August 2008 | Low-cost generic programs help make medication co-pays more affordable. |

SELECTED INVITED PRESENTATIONS

1. Justifying, Implementing, and Financing Investigational Drug Services at Shands Hospital. Presented at the ASHP Midyear Meeting, Las Vegas, Nevada, December 1990.
2. Computerization of an Investigational Drug Service Data Base. Presented at the University Hospital Consortium's Technology Advancement Center Meeting, Chicago, Illinois, March 1991.
3. Formulary Management of Biotechnology Through a Subcommittee. Presented at the Biotechnology Institute, Charlotte, North Carolina, September 1993, August 1994.
4. Justifying, Implementing and Financing an Investigational Drug Service - an Update. Presented at the FSHP annual meeting, Orlando, Florida. August 19, 1994.
5. Participant in "Today in Cardiology" Roundtable. The Safety of Cox-2 Inhibitors in Patients with CHD. Anaheim, California, February 2001.
6. Managing Hypertension in CAD Patients: What Have the Clinical Trials Taught Us? Are the JNC VI guidelines being followed in the 21st Century? American College of Cardiology, Twenty-first annual perspectives on New Diagnostic and Therapeutic Techniques in Clinical Cardiology. January 27, 2002.

7. Managing Hypertension in Patients with CAD. Florida Society of Health System Pharmacists annual meeting, Jacksonville, Florida. November 10, 2002.
8. Hypertension: New Observations on Gender, Ethnicity, and Diabetes from INVEST. American College of Cardiology, Twenty-second annual perspectives on New Diagnostic and Therapeutic Techniques in Clinical Cardiology. January 24, 2003.
9. Managing Blood Pressure and Cardiovascular Risk in the Complex Patient – a Focus on the Guidelines and the Evidence. North Central Florida Society of Health System Pharmacists. March 31, 2004.
10. Pharmacologic Management of Hypertension. American College of Cardiology, March 11, 2006.
11. Women’s Heart Health: An Update. Shands Women’s Advantage, February 15, 2007
12. CAD, Inflammation and COX-2 Inhibitors. North Central Florida Society of Health System Pharmacists. March 14, 2007.
13. Women’s Heart Disease – New Prevention Guidelines. Prime Time Institute, Gainesville, Florida. May 31. 2007.
14. Facilitating Investigator Initiated Research within the Cardiovascular Medicine Division, Cardiovascular Grand Rounds, Gainesville, Fl. August 23, 2007.
15. Cardiovascular Medications – an update. Oak Hammock Community, Gainesville, Florida. October 2, 2007
16. Hypertension: Evidence Based Treatments to Improve Patient Outcomes. American Health Resources, CVS Pharmacists, Ocala and Tampa, Florida. October 14 and 29, 2007.
17. Supplements: Where’s the Evidence? American College of Cardiology Annual Scientific Sessions, Chicago, Illinois, March 2008.
18. Investigation of the early effects of ACE-I on Glucose Tolerance During Treatment with HCTZ in Patients with Hypertension and Metabolic Syndrome. Center for Pharmacogenomics Seminar, October 2008.
19. Antidepressant mediations in the cardiovascular patient. American College of Cardiology Annual Scientific Sessions, Pharmacology Program, Orlando, Florida, March 2009.
20. Programs for getting and keeping your patients on their medications. American College of Cardiology Annual Scientific Sessions, Orlando, Florida, March 2009.
21. Brown Bag Supplements: Where’s the Evidence? Preventive Cardiovascular Nurses Association Annual Meeting, Dallas, Texas. April 2009.
22. Herbs and Other Alternative Therapies: Just What Is Your Patient Taking? Cardiovascular Grand Rounds, Gainesville, Fl. January 14, 2010.
23. Rethinking Lower BP Goals For Diabetics With Documented Coronary Artery Disease. American College of Cardiology, 2010 Scientific Sessions, Late Breaking Clinical Trials Presentation, Atlanta, Georgia, March 14, 2010.
24. Drug Induced Diabetes – Insights for the Care of Patients at Risk. Baptist Hospital cardiovascular Conference Series, Miami FL October 7, 2010.
25. Supplements and OTC’s in the Cardiovascular Patient, Core Curriculum for the Cardiovascular Clinician, Heart House, Washington, DC, October 23, 2010.
26. New Drugs That Will Change Your Practice. American College of Cardiology, 2010, Core Curriculum for the Cardiovascular Clinician, Heart House, Washington, DC, October 23, 2010.
27. Hypertension: How Low Should We Really Go in the Patient with Diabetes? American College of Cardiology, 2011, Scientific Sessions, New Orleans, LA.
28. Cardiovascular Implications of Dietary Supplements. American College of Cardiology, 2012, Scientific Sessions, Chicago, IL.
29. BP: How Low Should We Go and How Do We Get There? American College of Cardiology, 2012, Scientific Sessions, Chicago, IL.
30. CCA Team-Based Maintenance of Certification (Test Your Knowledge without a Test). American College of Cardiology, 2012, Scientific Sessions, Chicago, IL.

31. Use of Generic Medications in the Management of Resistant Hypertension. American College of Cardiology, 2012, Scientific Sessions, Chicago, IL.
32. Dietary Supplements: Use and Misuse. American College of Cardiology, 2012, Scientific Sessions, Chicago, IL.
33. Supplements and OTC's in the Cardiovascular Patient. 2012 Foundations for Practice Excellence: Core Curriculum for the Cardiovascular Clinician. October 2012, Orlando, FL.
34. New Drugs: Cardiovascular Pharmacology Update. 2012 Foundations for Practice Excellence: Core Curriculum for the Cardiovascular Clinician. October 2012, Orlando, FL.
35. Anticoagulation and Antiarrhythmics – An Update. 2012 Foundations for Practice Excellence: Core Curriculum for the Cardiovascular Clinician. October 2012, Orlando, FL.
36. Pharmacometabolomics and Pharmacogenomics in Understanding Drug-Induced Adverse Responses. Pharmacogenomics Research Network Fall 2012 Scientific Meeting, Seattle, WA.
37. Dietary Supplements: Use and Misuse. 36th Annual Cardiology Update, February 2013, El Paso, TX.
38. Depression and Cardiac Patient: What the Cardiac Care Team Should Know to Safely Prescribe Anti-Depressants. American College of Cardiology, 2013, Scientific Sessions, San Francisco, CA.
39. Depression and CAD: How to Manage the Sad Heart. American College of Cardiology, 2013, Scientific Sessions, San Francisco, CA.
40. Cardiac Care Associate Maintenance of Certification: Guideline Case Studies for the Cardiac Care Team. American College of Cardiology, 2013, Scientific Sessions, San Francisco, CA.
41. Generic Antihypertensive Drugs. The American Society of Hypertension 2013 Scientific Annual Meeting, San Francisco, CA.
42. Treating Resistant Hypertension with Generic Drugs. The American Society of Hypertension 2013 Scientific Annual Meeting, San Francisco, CA.
43. A Metabolomic Approach into Addressing the Question Whether Multiple Drug-Induced Adverse Metabolic Effects Share a Common Mechanism. American Heart Association 2013 Scientific Sessions, Dallas, TX.
44. Dietary Supplements: The Latest in Use and Abuse. Central Florida Society of Health Systems Pharmacists, November 2013, Orlando, FL.
45. Personalized Medicine and the Role of the Pharmacist. 2014 Midwest Pharmacy Expo, Altoona, IA.
46. Cardiac Care Associate Maintenance of Certification: Guideline Case Studies for the Cardiac Care Team. American College of Cardiology, 2014, Scientific Sessions, Washington, DC
47. Drugs and Food – what do we really need to be concerned about? Cardiovascular Fellows Conference, University of Florida, Gainesville, FL August 2014
48. Clinical Research Concepts, IRB Rules, and Regulations. Master's in Public Health Orientation Program, University of Florida, Gainesville, FL August 2014
49. Hypertension – What's New in the Guidelines? The Larry Lopez Cardiovascular Seminar: Redefining and Refining the Treatment Approaches to Cardiovascular Disease. Orlando, Florida, October, 2014
50. Dyslipidemia – What's new in the Guidelines? The Larry Lopez Cardiovascular Seminar: Redefining and Refining the Treatment Approaches to Cardiovascular Disease. Orlando, Florida, October, 2014
51. Dietary Supplements and the CV Patient-Helpful or harmful? The Larry Lopez Cardiovascular Seminar: Redefining and Refining the Treatment Approaches to Cardiovascular Disease. Orlando, Florida, October, 2014

52. Nuts and Bolts of Cardiovascular Pharmacology. American College of Cardiology – Core Curriculum for the Cardiovascular Clinician. National Harbor, MD, October 2014
53. Case Presentation: Which Drug For My Patient? American College of Cardiology – Core Curriculum for the Cardiovascular Clinician. National Harbor, MD, October 2014
54. Dietary Supplements in the CV Patient – Helpful or Harmful?. American College of Cardiology, March 2015 Scientific Sessions, San Diego, California.
55. Case Studies From the Guidelines for Clinicians. American College of Cardiology, March 2015 Scientific Sessions, San Diego, California.
56. What Do I Want to be When I Grow Up? Independent Investigator. American College of Cardiology, March 2015 Scientific Sessions, San Diego, California.
57. Underappreciated Management Issues in Hypertension: Supplements and Interacting Substances That Can Impact Management. American Society of Hypertension, May 2015 Scientific Sessions, New York, New York.
58. Supplements and OTC Drugs: Culprits to Consider When Evaluating Hypertension. American Society of Hypertension, May 2015 Scientific Sessions, New York, New York